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61. SUMMARY
Modified vaccinia virus Ankara (MVA) is a highly attenuated vaccinia virus strain
developed during the smallpox eradication campaign. Nowadays recombinant
attenuated poxviruses gain importance as live carrier vaccines against different
infectious diseases and in cancer therapy.
The aim of this work was to develop recombinant viral vectors, for presentation of a
foreign antigen on the surface of extracellular enveloped particles (EEV). First, it was
tested whether significant amounts of this viral form are produced by MVA in
comparison to replication competent and widely used vaccinia virus strains. Using a
number of independent approaches it could be shown that MVA infection in primary
chicken embryo fibroblasts results in the production of enveloped viruses, but
strikingly most of these were not released into the culture medium but remained
attached to the plasma membrane. The results also showed that the replication
competent vaccinia virus IHD-J is more efficient in trans-Golgi-network-wrapping and
in releasing enveloped virions into the extracellular medium, while the WR strain is
less efficient than MVA.
Two different strategies were followed to target the recombinant protein to the
surface of extracellular enveloped viruses. Since it was shown that non-vaccinia virus
proteins can be incorporated to some extent into the outer membrane, a native model
type II membrane protein was used. To increase the chance of foreign protein
incorporation a fusion protein was used which consisted of the transmembrane
domain of a protein known to be specific for the outer membrane of extracellular
enveloped virus and the extracellular domain of the foreign antigen which was used
in its native form.
The data show that both proteins were incorporated into the extracellular enveloped
virions produced in MVA infected chicken embryo fibroblasts, albeit with low
efficiency. The transmembrane domain of the EEV specific protein was not sufficient
to target the foreign protein specifically to the outer envelope.
72. INTRODUCTION
The Poxviridae comprise a large family of complex DNA viruses that replicate in the
cytoplasm of vertebrate and invertebrate cells. The most notorious member, variola
virus, caused smallpox and consequently had a profound impact on human mortality
in historical times. Smallpox was eradicated in 1977, nearly two centuries after the
introduction of prophylactic inoculations with cowpox and vaccinia virus. Vaccination
with vaccinia virus contributed to present concepts of infectious diseases and
immunity. Additionally, vaccinia virus was the first animal virus seen microscopically,
grown in tissue culture, accurately titrated, physically purified, and chemically
analyzed (Moss, 1996b).
Due to the ease of generating mutants, vaccinia virus has become a popular
eukaryotic expression system. Since vaccinia virus can induce effective T cell
immunity, against itself as well as to foreign proteins cloned into its genome,
recombinant attenuated poxviruses are attractive candidates to be utilized in cancer
therapy and vaccination programmes (Brochier et al., 1991; Hanke and McMichael,
2000) for review see (Moss, 1996a).
2.1 Historical background of vaccination
The first effective method of prevention of any infectious disease was applied to
smallpox as early as the 10th century by the intranasal insufflation of dried smallpox
scrab material or the inoculation of pustule fluid or scrab material into the skin, a
practice called „inoculation“ or „variolation“. If the material used contained active
virus, such operations produced smallpox. But for reasons that are not well
understood, the disease induced in this manner was usually much milder than
„natural“ smallpox, with case-fatality rates of 1-2% instead of 20-30%. A major
disadvantage of variolation was that the virus was unchanged in virulence, and mild
cases of inoculation smallpox could give rise to severe and fatal attacks of smallpox
in contact persons (Fenner, 1988). In 1796 Jenner introduced cowpox virus, a related
Orthopoxvirus, for preventing smallpox (Jenner, 1959). He challenged persons who
had been injected with cowpox virus by inoculation with smallpox virus and showed
that they were completely protected. The new procedure became known as
vaccination (vacca = cow). By 1967 a Smallpox Eradication Unit was established at
WHO headquarters, with the aim of global eradication within a decade. The WHO
8program achieved this goal in October 1977, and the world was certified free of
endemic smallpox in 1979 (WHO, 1980).
2.2 Taxonomic classification of poxviruses
The general properties of Poxviridae include a large (250-350 nm) complex brick-
shaped virion containing enzymes that synthesize mRNA, a genome composed of a
single linear double-stranded DNA molecule of 130-300 kilobase pairs (kbp) with a
hairpin loop at each end, and a cytoplasmic site of replication. The Poxviridae are
divided into two subfamilies, Chordopoxviridae and Entomopoxviridae, based on
vertebrate and insect host range (for overview see table 1).
The similarity in restriction endonuclease maps of several Orthopoxvirus genomes
(Esposito and Knight, 1985; Mackett and Archard, 1979) has been substantiated by
more than 90% sequence identity of genes of vaccinia and variola viruses (Goebel et
al., 1990; Massung et al., 1994; Shchelkunov et al., 1993). For at least the last 100
years vaccination against smallpox has been carried out with a distinct species of
Orthopoxvirus now called vaccinia virus, which is different from cowpox virus, the
agent that Jenner used. Subsequently, some preparations of vaccine came from pox
lesions of horses and other lots were purportedly mixed with smallpox virus to
increase their „potency“. Vaccinia virus has no natural host, although it has been
isolated from buffalo in India (Dumbell and Richardson, 1993), and its origin has not
been resolved (Baxby, 1981). The restriction endonuclease maps of the genomes of
different strains of vaccinia virus from different parts of the world are very similar to
each other and quite distinct from variola virus, cowpox virus, and other members of
the poxvirus family that occur naturally (Esposito and Knight, 1985). It is not known
whether vaccinia virus is the product of genetic recombination, a new species derived
from cowpox or variola virus by prolonged serial passage, or the living representative
of a now extinct virus (Baxby, 1981).
Despite the profound differences in pathogenicity of variola, vaccinia and cowpox
viruses for humans, they are known to belong to the same Orthopoxvirus genus,
accounting for their ability to cross protect.
9Table 1: Family poxviridae (Moss, 1996b)
Subfamilies Genera Member viruses
Chordopoxviridae
(vertebrate poxviruses)
Orthopoxvirus Camelpox, cowpox,
ectromelia, monkeypox,
racoonpox, skunkpox,
taterapox, Uasin Gishu,
vaccinia, variola,
volepox
Parapoxvirus Auzduk disease,
chamois, contagious
ecthyma, orf,
pseudocowpox, parapox
of deer, sealpox
Avipoxvirus Canarypox, fowlpox,
juncopox , mynahpox,
pigeonpox,
psittacinepox, quailpox,
peacockpox,
penguinpox,
sparrowpox, starlingpox,
turkeypox
Capripoxvirus Goatpox, lumpy skin
disease, sheeppox
Leporipoxvirus Hare fibroma, myxoma,
rabbit fibroma, squirrel
fibroma
Suipoxvirus Swinepox
Molluscipoxvirus Molluscum contagiosum
Yatapoxvirus Tanapox, Yaba monkey
tumor
Entomopoxviridae
(insect poxviruses)
Entomopoxvirus A Melolontha melolontha
Entomopoxvirus B Amsacta moorei
Entomopoxvirus C Chironimus luridus
2.3 Modified vaccinia virus Ankara (MVA)
Although vaccination with vaccinia virus was a major achievement compared to
variolation, cases of severe side effects occurred. Congenital or acquired
immunodeficiency diseases, immunosuppression, and eczema were absolute contra-
indications to vaccination (Fenner, 1988). During the course of the eradication
campaign, several highly attenuated strains of vaccinia virus were developed to
overcome these risks. MVA was derived from vaccinia virus strain Ankara that was
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used in Turkey for vaccination against variola. The virus was attenuated by over 570
serial passages in chicken embryo fibroblast cells (CEF) (Mayr, 1975). The resulting
MVA strain lost the capacity to productively infect mammalian cells and suffered six
major deletions of DNA totaling 31,000 base pairs (bp). Compared to VV
Copenhagen one third of the genes that encode in particular for host range and
immune evasion factors are deleted or fragmented (Antoine et al., 1998). When
tested in a variety of animal species, MVA was proven to be avirulent even in
immunosuppressed animals (Mayr, 1978). Nevertheless, replication of viral DNA
appeared normal and both early and late viral proteins were synthesized. This finding
was surprising, since other vaccinia viruses with a restricted host range had lost this
ability (Drillien et al., 1981; Drillien et al., 1978). Proteolytic processing of viral
structural proteins was inhibited, for example in 4A and 4B, two major proteins of the
virus core. Correct proteolytic processing of the core proteins is essential for virion
morphogenesis, so only immature particles were detected by electron microscopy. In
human cells, the assembly of infectious MVA particles is blocked at an early stage.
Vaccinations of more than 125,000 humans with MVA showed no major cases of
side effects.
Despite the inability of MVA to produce infectious progeny, recombinant viruses were
able to synthesize high levels of a foreign protein in human cells, demonstrating the
potential of MVA to serve as an exceptionally safe and highly efficient expression
vector (Sutter and Moss, 1992).
2.4 Genome of vaccinia viruses
Poxviruses have linear double-stranded DNA genomes that vary from about 130 kbp
in parapoxviruses to about 300 kbp in avipoxviruses. Inverted terminal repeats
(ITRs), which are identical but oppositely oriented sequences at the two ends of the
genome are present in all poxviruses examined. The length of the ITRs are variable
even within a genus (Moss, 1996b).
The two strands of vaccinia virus DNA are connected by hairpin loops to form a
covalently continuous polynucleotide chain (Baroudy et al., 1982; Geshelin and
Berns, 1974). The genomes of several VV strains have been sequenced, including
Copenhagen strain (Goebel et al., 1990) and MVA (Antoine et al., 1998). The
genome of MVA is 178 kb in length, significantly smaller than that of the vaccinia
Copenhagen genome, which is 192 kb. The 193 open reading frames (ORF) mapped
in the MVA genome probably correspond to 177 genes, 25 of which are split and/or
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have suffered mutations resulting in truncated proteins. Essential genes map within
the highly conserved central region of the genome, whereas many of the genes that
are dispensable for replication in tissue culture are closer to the ends. The apparent
absence of introns, the short promotor sequences, and the relatively small sizes of
many ORFs account for the packing of about 150-200 genes into the orthopoxvirus
genome (Goebel et al., 1990). Both strands of the DNA are transcribed, yet extensive
overlap of the ORFs is uncommon.
The convention adopted for naming the orthopoxvirus ORFs consists of using the
Copenhagen HindIII restriction endonuclease DNA fragment letter from A to O,
followed by the ORF number inside a specific HindIII fragment (from left to right), and
L or R, depending on the direction of transcription of the ORF (Rosel and Moss,
1985).
Several different nomenclatures are in use for VV proteins. Initially they were named
according to their apparent molecular weight (e.g. p21, p37 etc.), or their enzymatic
activity (e.g. DNA polymerase). In recent years, however, as the proteins could be
assigned to their corresponding genes in the viral genome, mostly the gene names
are used. Purified VV virions contain more than 110 proteins that are usually
synthesized late (Carrasco and Bravo, 1986; Essani and Dales, 1979; Jensen et al.,
1996). Per definition, all proteins present in the virions could be called structural VV
proteins. However, not all of these have necessarily a structural role, but rather are
packaged because their enzymatic activities are needed for the process of early
transcription upon infection of the cell (Gershon and Moss, 1990). The virion proteins
are roughly divided into core and membrane proteins according to their solubility in
non-ionic detergents under reducing conditions.
Many viral proteins, including some structural ones, modulate the course and
pathogenesis of viral infection in the host animal and are as such not essential for
replication in cultured cells. All VV proteins are roughly classified into early and late
dependent on whether they are synthesized before or after DNA replication. Many
viral enzymes are synthesized late, and are packaged into the virion to function
during virus entry or early viral transcription. Other viral enzymes are synthesized
early, and are required for DNA replication and late viral transcription.
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2.5 Life cycle of vaccinia virus
The infection of a host cell by a virus can be divided into several steps (Levine,
1992):
1. Adsorption: Binding of the virus to receptors on the plasma membrane of the host
cell.
2. Penetration: Entry of the virus into the host cell by penetrating the plasma
membrane or endosome and delivery of the viral core into the cytoplasm.
3. Uncoating: Release of the viral genome into the host cell.
4. Synthesis of early viral proteins.
5. Replication of the viral genome.
6. Synthesis of late viral proteins.
7. Assembly: Posttranslational modification of viral and structural proteins and
assembly of the viral particles.
8. Release of infectious particles (specific or by lysis of the host cell).
A schematic overview of the complex assembly process is depicted in Fig. 1
(Sanderson, 1999).
2.5.1 Adsorption and penetration
The entry pathway of poxviruses, including vaccinia virus, the prototype of this family,
is not well characterized. Studies of poxviruses are complicated by the fact, that two
structurally and antigenically distinct, infectious forms exist: intracellular mature virus
(IMV) and extracellular enveloped virus (EEV). Structurally, EEV consists of an IMV
with an additional outer membrane containing proteins that are absent from IMV. The
amount of EEV produced varies between different vaccinia virus strains and host cell
types (Payne, 1980).
Vertebrate poxviruses were thought to enter cells by phagocytosis (viropexis) (Dales,
1964). When entry by fusion of the virus envelope with the host cell membrane was
discovered for insect poxviruses (Granados, 1973), adsorption and penetration of
vaccinia virus was re-examined. Studies indicated the occurrence of direct fusion
between the envelope of the attached virus particles and the plasma membrane of
the cell. Since also poxvirus particles closed within phagosomes were seen, those
findings suggested, that vaccinia virus can enter cells by membrane fusion as well as
by phagocytosis (Armstrong et al., 1973). In all of these experiments it was not
distinguished between IMV and EEV. Payne and Norrby (Payne and Norrby, 1978)
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examined the adsorption and penetration of IMVs and EEVs separately, and came to
the conclusion, that intracellular and extracellular viruses enter the cell by different
mechanisms. Kinetic studies showed, that EEV penetrated cells more rapidly than
IMV (Domes, 1990; Payne and Norrby, 1978). The fusion of EEV with the plasma
membrane of host cells presents an interesting topological problem. In fact, fusion of
EEV would be expected to release IMV into the cytoplasm, facing the problem of
removal of the IMV membrane and virus uncoating. Ichihashi (Ichihashi and Oie,
1996) proposed a model of EEV entry, assuming that EEV entry consists of binding
to the cell, endocytosis, disruption of the EEV outer membrane within an acidified
endosome, fusion of the exposed IMV with the endosomal membrane and release of
the core into the cytoplasm. This model was strongly supported by Vanderplasschen
et al. (Vanderplasschen et al., 1998a). The receptors responsible for virion entry
have not been identified yet. A monoclonal antibody, called B2, which recognizes a
trypsin-sensitive cell surface protein and inhibits the binding of IMV to cells was
isolated (Chang et al., 1995). This antibody inhibits IMV binding sterically but the
inhibition is incomplete, suggesting that there is more than one IMV receptor
(Vanderplasschen et al., 1997). More recently it was shown, that binding of IMV
activates a signaling cascade, linked to the formation of actin and ezrin containing
protrusions at the plasma membrane, that seems to be essential for the entry of IMV.
EEV appeared to enter the cell without the need for signaling and actin/membrane
rearrangements (Locker et al., 2000). Electron micrographs suggested that the cores
derived from both the IMV and EEV enter the cell at the plasma membrane where
they discard all the surrounding membranes (Locker et al., 2000). In contrast to what
would be expected of a simple fusion event, none of the IMV- and EEV-membrane
proteins appear to be implanted into the plasma membrane since they could not be
detected at the plasma membrane by immunoelectron microscopy. Instead, viral
membrane fragments that were attached to the cell surface or in close proximity to
the plasma membrane were decorated by antibodies to viral proteins (Locker et al.,
2000; Pedersen et al., 2000). Because of those findings it was proposed that, rather
than entering by membrane fusion, both viruses seem to undergo a „membrane
shedding“ or „membrane unfolding“ at the plasma membrane, releasing the
underlying core for delivery into the cytoplasm. This hypothesis leaves open how the
core that is released at the plasma membrane, is subsequently translocated across
that same membrane. While there is little consensus on the exact pathway, it is
generally accepted that the first step of uncoating results in the delivery of VV cores,
that contain the genome and associated viral enzymes into the cytoplasm
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(Hollinshead et al., 1999; Locker et al., 2000; Moss, 1990; Pedersen et al., 2000;
Vanderplasschen et al., 1998a).
2.5.2 Synthesis of VV-proteins and DNA replication
Besides DNA, also virus-encoded enzymes are present in the core, including a
multisubunit DNA-dependent RNA polymerase, a transcription factor, capping and
methylating enzymes, and a poly(A) polymerase, all of which form a complete
apparatus for the transcription of mRNA. When the core enters the cytoplasm,
approximately 100 genes (about half of the virus genes) are transcribed by the viral
RNA polymerase. These early genes encode proteins involved in stimulation of the
growth of neighboring cells, defense against host immune responses, replication of
the viral genome, and transcription of the intermediate class of viral genes. During
poxvirus replication, concatemeric intermediates that are resolved into unit-length
genomes are formed. The replicated DNA molecules provide the templates for the
successive expression of intermediate and late genes. Intermediate genes are less
numerous and encode mostly for factors required for late transcription. During virus
infection intermediate genes are only expressed once DNA replication has
commenced, as late genes are expressed once the late transcription factors are
available. They encode the structural proteins of the virus, enzymes that are to be
packaged into virions for early transcription, and additional virulence factors. In
general, late proteins are expressed at higher levels than early proteins due to their
requirement in stoichiometric rather than catalytic amounts. Each temporal class of
genes has its own characteristic promotor sequences that are recognized by specific
viral proteins, providing the basis for a programmed cascade mechanism of gene
regulation.
DNA replication has long been known to occur in distinct cytoplasmic sites, called the
viral factories (Cairns, 1960). It was recently shown that these sites do not lie „free“ in
the cytoplasm, but instead were found surrounded by ER membranes (Tolonen et al.,
2001). This ER wrapping process correlated with DNA replication. About 3 hours post
infection the entire replication site appeared to be ER enclosed, and this wrapping
persisted throughout infection until the first evidence of virion assembly was seen.
Interestingly, ER-wrapping coincided with a peak in viral DNA synthesis implying that
wrapping may promote viral replication. ER wrapping may supply the replicating DNA
a cytoplasmic scaffold as well as create a microenvironment that supports DNA
synthesis (Tolonen et al., 2001).
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2.5.3 Assembly
VV life cycle takes place entirely in the cytoplasm of the infected cell, where
morphogenesis proceeds through a well-synchronized series of events. Assembly of
VV starts at 5 to 6 h.p.i. with the formation of typical crescent-shaped membranes
modified by viral membrane proteins. These crescents are perfectly spherical
segments of membranes with a thickness of 8 nm and a diameter of 280 nm (Sodeik
et al., 1994). According to the classical model of VV assembly, membrane crescents
contain a single biological membrane bilayer that has no continuities to cellular
membrane systems but ends openly in the cytosol (Dales and Mosbach, 1968;
Hollinshead et al., 1999; Stern and Dales, 1974). It has been proposed that the
crescents assemble de novo in the cytoplasm from cellular lipids and viral membrane
proteins by a unique viral mechanism. The viral DNA is incorporated into the
spherical immature virion (IV), and after several internal structural changes most
likely induced by proteolytic cleavage of major core proteins, an intracellular mature
virus (IMV) is formed. The core was thought to contain a proteanaceous core
membrane enclosing the viral DNA, DNA associated proteins and viral enzymes.
Lateral bodies are located on both sides of the core that therefore appears as a
biconcave disk and has a dumb bell shape in cross sections. One outer membrane
that contains both proteins and lipids, encloses core and lateral bodies, to build the
mature IMV particle. In this model, IMV was postulated to be surrounded by  a single
lipid bilayer made de novo in the cell.
This model was challenged in 1993 by Sodeik et al. (Sodeik et al., 1993), who
showed data to suggest that the crescent-shaped membranes are composed of two
tightly apposed membranes derived from a cisterna of the smooth ER (Sodeik et al.,
1993; Sodeik and Krijnse-Locker, 2002). It was subsequently shown that several viral
membrane proteins are co-translationally inserted into the ER and retained in smooth
ER membranes. Since these membrane proteins localize also to the crescent-
shaped membranes, it was postulated that interactions between these ER-retained
viral membrane proteins caused two lipid bilayers of a cellular ER cisterna to become
so tightly apposed that they could easily be mistaken for one bilayer only.
Furthermore these proteins were at least in part responsible for the formation of the
characteristic crescent-shape of the viral membranes; reviewed in (Sodeik and
Krijnse-Locker, 2002). These crescents engulf electron-dense material composed of
viral core proteins and generate the completely spherical IV (Fig. 2A). Upon DNA
uptake the spherical IV particles develop an internal core surrounding the DNA and
mature into the infectious form of the virus, the intracellular mature virus (Fig. 2B).
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Figure 1: Assembly of vaccinia virus in a human cell (Sanderson, 1999). SER = smooth
endoplasmic reticulum; RER = rough endoplasmic reticulum. (a) Vaccinia virus
morphogenesis starts in cytoplasmic factories with the formation of membrane crescents,
which extend to form spherical immature virus (IV) particles. (b) IV particles are non-infectious
until they undergo morphological condensation into brick-shaped IMV particles. (c) During
infection, most IMV particles remain within the cell until they are released by cell lysis.
However, some IMV particles become enveloped by membranes derived from either the
trans-Golgi network (TGN) or tubular endosomes (d) to form intracellular enveloped virus
(IEV) (e). (f) Proteins within the outer membrane of IEV particles induce the polarised,
unidirectional polymerization of actin, which propels the particle towards the plasma
membrane and assists the infection of neighboring cells. (g) During this process, the outer
membrane of the IEV particle fuses with the plasma membrane of the cell, exposing an
infectious particle on the cell surface and leaving proteins that induce actin polymerization
within the plasma membrane. (h) If these particles remain attached to the cell they are called
cell-associated enveloped virus (CEV); (I) however, if they are released from the cell they are
called extracellular enveloped virus (EEV). (j) In addition to the classical mechanism of
vaccinia virus assembly described above, EEV particles can also form via direct budding of
IMV particles through the plasma membrane. This alternative mechanism of EEV formation
might be facilitated by the transport of viral glycoproteins from the TGN to the plasma
membrane (k).
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The IMV is formed after the IV undergoes a major structural transformation, which
coincides with the cleavage of several core proteins (Lee and Hruby, 1994; Moss and
Rosenblum, 1973; Silver and Dales, 1982; Vanslyke et al., 1991). This cleavage
presumably triggers the transition from the spherical IV to the brick-shaped IMV, and
the generation of the morphologically and biochemically distinct core structure of the
IMV. The IMV is roughly brick-shaped and measures around 300-310 x 240-245 x
110-130 nm3. IMVs contain around 90% protein, 6% lipid, and 3% DNA, and weigh 5
x 10-15 g (Smadel, 1942; Zwartouw, 1964). In contrast to the classical model, the IMV
is thought to contain two lipid bilayers that are very closely juxtaposed. Most recently
it was proposed that the structure of the IMV is exceedingly more complex than
presented above, and that the particle might be composed of one continuous folded
membrane cisterna (Griffiths et al., 2001a; Griffiths et al., 2001b). One fold of the
cisterna seems to enclose the genome and separates the genome from another
(cytosolic) compartment. Moreover, the cisternae enclosing the DNA seem to be
continuous with the membrane cisterna that surround the particles and seal the virion
off at one side. The lateral bodies are proposed to be the sites where the outer
membrane cisternae contact the viral core (Sodeik and Krijnse-Locker, 2002).
2.5.4 Release
IMVs provide the majority of infectious progeny of VV and remain inside the infected
cell until cell-lysis but can also bud off under some conditions (Tsutsui, 1983). A
fraction of the IMVs becomes further enveloped by a double membrane derived from
the early tubular endosomes (Tooze et al., 1993) or trans-Golgi network (Schmelz et
al., 1994) (Fig. 2C). Envelopment of IMV must involve the specific interaction
between one or more IMV surface proteins and the cytosolic domain of one or more
EEV proteins, which become enriched in the wrapping membranes. The efficiency
and degree of this wrapping process depends on the combination of virus strain and
cell type used. Once envelopment is complete, the virus particles are surrounded by
two additional membranes compared to the IMV and are called intracellular
enveloped virus (IEV). For a while it was thought that the IEVs polymerize actin-tails
with which they are actively moved through the cytoplasm towards the plasma
membrane, with which they will then fuse (Fig. 2D) to release the extracellular
enveloped virus (EEV) into the extracellular environment (Cudmore et al., 1995).
Recently, however, it was shown that IEVs move in a kinesin-dependent fashion on
microtubules towards the plasma membrane. Upon fusion of the outer-most
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membrane of the IEV with the plasma membrane actin tails are made at this cellular
membrane. The purpose of these tails appears to be the formation of long plasma
membrane-derived filopodia, with an EEV attached on their tip (called CEV, see
below), a process that may aid in virus cell-to-cell spread (Hollinshead et al., 2001;
Moss and Ward, 2001; Rietdorf et al., 2001; Ward and Moss, 2001). These data are
consistent with other results showing that the EEV is important for virus
dissemination both in vitro and in vivo (Appleyard et al., 1971; Blasco and Moss,
1991; Boulter and Appleyard, 1973; Payne, 1980; Payne and Kristensson, 1985).
EEVs contain an additional envelope compared to IMV and are actively released
from the infected cell. With most strains of VV a substantial fraction of the EEV
remains attached to the cell surface and is termed cell-associated enveloped virus
(CEV) (Blasco and Moss, 1992), constituting the viral form that is attached to the
actin-tail containing filopodia. The EEV protein required for both microtubule- and
actin-dependent motility is thought to be the gene product of A36R. This protein may
indirectly bind to the so-called TPR domain of conventional kinesins’ light chain
(Rietdorf et al., 2001), thus mediating the observed microtubule-dependent
movement. At the plasma membrane the same protein then may become tyrosine
phosphorylated by cellular scr-kinases, a prerequisite for the formation of actin tails
(Frischknecht et al., 1999a). With the formation of the IEV/EEV VV has thus evolved
a very efficient and rapid mechanism for virus egress and cell-to-cell spread.
2.6 Infectious forms of vaccinia virus
As mentioned above, five morphologically different viral forms exist: immature virus
(IV), intracellular mature virus (IMV), intracellular enveloped virus (IEV), cell-
associated enveloped virus (CEV), and extracellular enveloped virus (EEV). IMV and
CEV/EEV are the infectious forms of the virus, that stay inside the infected cell until
lysis (IMV) or are actively released (CEV and EEV) and enter the cells by different
mechanisms.
The properties of the additional envelope present on CEV/EEV are responsible for
these differences.
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Figure 2: EM pictures of vaccinia virus virions at different stages of assembly. (A) Spherical
IVs, IV uptaking DNA  (✻). (B) IMVs accumulating inside the cell. (C) TGN-wrapping of IMVs
(arrows pointing to the wrapping membranes) (D) IEV fusing with the plasma membrane
(arrow), CEV attached to the cell surface.
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2.6.1 EEV specific proteins
At least 10 proteins which are absent from the IMV are associated with the outer
envelope (Payne, 1978; Payne, 1979) and five  of which have been identified, which
endow EEV with different biological and immunological properties.
These are: A56R, encoding the virus haemagglutinin (HA), a heavily glycosylated
protein of 86 kDa (Payne and Norrby, 1976; Shida, 1986); F13L, encoding a 37 kDa
protein, p37 (Hirt et al., 1986); B5R, encoding a 42 kDa glycoprotein, gp42
(Engelstad et al., 1992; Isaacs et al., 1992); A33R, encoding a 23-28 kDa
glycoprotein, gp23-28 (Roper et al., 1996); and A34R, encoding a triplet of
glycoproteins of 22-24 kDa, gp22-24 (Duncan and Smith, 1992). In addition, the
A36R, encoding a 45-50 kDa protein, p45-50 (Parkinson and Smith, 1994) is present
in IEV but not IMV, CEV or EEV particles (van Eijl et al., 2000). Lastly, the F12L
protein was identified recently as a 65 kDa protein (Zhang et al., 2000), which, like
the A36R protein, is present only in IEV particles (van Eijl et al., 2000).
None of the EEV- and IEV-specific proteins are required for the formation of IMV, but
they have different roles thereafter. In the absence of F13L (Blasco et al., 1991) or
B5R (Engelstad and Smith, 1993; Wolffe et al., 1993), the wrapping of IMV by TGN
membranes to form IEVs, is reduced or abolished and therefore subsequent stages
of morphogenesis are inhibited. Deletion or repression of A33R (Roper et al., 1998),
A34R (Duncan and Smith, 1992; McIntosh and Smith, 1996; Sanderson et al., 1998)
or A36R (Parkinson and Smith, 1994; Sanderson et al., 1998; Wolffe et al., 1998)
enables IEV, CEV and EEV to be formed, but cell-to-cell virus spread is reduced and
these mutants have a small plaque phenotype (Zhang et al., 2000).
Enhanced levels of EEV are released when gene A33R (Roper et al., 1998) or A34R
(McIntosh and Smith, 1996) is deleted, but without A34R the EEV has a reduced
infectivity. Enhanced levels of EEV are also formed when the A34R (Blasco et al.,
1993) or B5R proteins (Herrera et al., 1998; Mathew et al., 1998; Mathew et al.,
2001) are mutated.
The loss of the A36R (Parkinson and Smith, 1994) or F12L (Zhang et al., 2000)
genes caused a reduction in EEV formation. For all theses mutants the production of
intracellular actin tails is reduced or abolished, providing a direct correlation between
actin tail formation and virus cell-to-cell spread. Recently it was shown that A36R is
required for both microtubule-mediated IEV movement and actin tail formation at the
plasma membrane (Rietdorf et al., 2001).
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The only IEV or EEV-specific protein not required for EEV formation is A56R
(Ichihashi and Dales, 1971; Sanderson et al., 1998).
Table 2: Properties of vaccinia virus mutants lacking specific EEV proteins (Smith and
Vanderplasschen, 1998)
Mutant Plaque size IMV IEV EEV Actin tails Virulence
vDA33R tiny 2-3 x Ø Incomplete
wrapping
2-4 x ≠ no, only
short+slender
?
vDA34R tiny normal few 19-24 x ≠
infectivity 5x
Ø
no attenuated
vDA36R small normal normal 3 x Ø no attenuated
vDA56R normal normal normal normal normal virulent
vDB5R small normal few 5 x Ø few attenuated
vDF12L tiny 2 x Ø normal 7 x Ø few attenuated
vDF13L tiny normal few 5 x Ø few attenuated
2.6.2 Properties of the CEV/EEV envelope
The presence of different proteins on the surface of IMV and EEV give these virions
different biological and immunological properties that are adapted to their different
roles in VV pathogenesis. As mentioned before, EEV and IMV bind to distinct cellular
receptors and penetrate cells by different mechanisms. Moreover, EEV, in contrast to
IMV, is resistant to antibody neutralization (Ichihashi, 1996; Vanderplasschen et al.,
1997). A major difference between IMV and EEV is also that IMV excludes host
proteins from its surface whereas EEV does not. Vanderplasschen et al.
(Vanderplasschen et al., 1998b) suggested that the incorporation of host complement
control proteins into the envelope of EEV makes these particles resistant to
complement.
2.7 Modern vaccines
Due to modern safety requirements vaccination procedures carried out like „in the old
days“ are no longer an option. Safety and effectiveness are prerequisites for vaccine
development. Since MVA has shown to be an exceptionally safe live vaccine and has
the potential to serve as an expression vector for foreign proteins, this highly
attenuated vaccinia virus strain is a candidate to be used as a non-virulent vector for
heterologous antigens. Understanding of the vertebrate immune system helps to
generate vaccines with increased efficiency in modulating the immune responses.
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Invading organisms or components of those have to be evaluated for their non-self
origin by innate immunity. Recognition as such leads to activation of host defense.
The innate immune system therefore uses germline-encoded proteins that are
expressed constitutively or are induced rapidly within hours following infection.
Macrophages attack invading microorganisms upon detection, and further activate
immune responses by releasing proinflammatory mediators.
Vertebrates have developed an acquired immunity that provides a higher degree of
structural specificity. Acquired immunity is provided by B and T lymphocytes each of
which express distinct cellular or soluble antigen receptors that have arisen by
somatic gene rearrangement and are selected for foreign antigen reactivity within
days.
The humoral immune response is driven by B lymphocytes which present highly
variable immunoglobulins as antigen receptors on their surface. After contact with an
antigen naive B cells differentiate into plasma cells which secrete high amounts of
specific antibody, and into memory cells which allow a fast antibody release after a
renewed antigenic contact. Antibodies, which bind with a high affinity to toxins,
viruses or bacteria are able to neutralize those pathogens. Mostly, antibodies are
covering the pathogens and bind to the Fc-receptor on phagocytes, mediating their
uptake and degradation.  Intracellular pathogens like viruses can be eliminated by
another mechanism. Degradation products are presented on the cell surface via
MHC class I molecules, this counts also for viral proteins after infection. Cytotoxic T
cells (CTL) recognize peptides presented by MHC class I molecules, which are
present on the surface on all nucleated cells. When the peptide presented is
recognized as non-self the infected cell will be killed. The demand for an efficient
vaccine should be the activation of both systems, B and T cell immunity.
2.8 Aim of the work
MVA is increasingly becoming an important candidate to be used as an attenuated
live vaccine against various diseases in humans. Most studies on VV particles have
been carried out with the replication competent vaccinia virus strains IHD-J and WR.
In this work the ability of MVA to produce enveloped viral forms was one focus of
investigation. Those enveloped virions are of special interest, since their outer
envelopes are able to incorporate foreign and cellular proteins.
It is known that MVA, like other VV strains, induces effective T cell immunity against
recombinant proteins even though ist replication is blocked in mammalian cells.
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Presentation of the foreign antigen on the surface of the viral particle could lead to
induction of B cell immunity and therefore modulates the type of immune response.
The aim of this work was the presentation of heterologous antigens on the outer
surface of MVA virions. For reason mentioned above, extracellular enveloped virus
was chosen as the viral particle of integration. The model antigen used in this work
was the hemagglutinin of canine distemper virus (CDV.H), a type II transmembrane
glycoprotein. Recombinant viruses containing the wildtype CDV.H or chimeric
proteins consisting of the transmembrane domain of known EEV specific proteins
and the extracellular domain of CDV.H should be produced and presentation of the
foreign protein on the surface of EEV characterized.
24
3. MATERIALS
3.1 Abbreviations
AB/AM Antibiotic-antimycotic solution
Amp Ampicillin
APS Ammonium peroxidisulfate
AraC Arabinosylcytosine
ATCC American Type Culture Collection
BSA Bovine serum albumin
CEV Cell associated virus
CPE Cytopathic effect
DMSO Dimethylsulfoxide
EDTA Ethylenediaminetetraacetic acid
EEV Extracellular enveloped virus
EGTA Egtazic acid
EM Electron Micoscropy
ER Endoplasmatic reticulum
EtBr Ethidium bromide
FCS Fetal calf serum
GFP Green fluorescent protein
HEPES N-[2-Hydroyxlethyl]piperazine-N‘-[2-ethanesulfonic acid]
h.p.i. hours post infection
IMCBH N1-Isonicotinoyl-N2-3-Methyl-4-Chlor-Benzoyl-Hydrazin
IEV Intracellular enveloped virus
IMV Intracellular mature virus
IV Immature virus
LB Luria-Bertani bacterial medium
m.o.i. Multiplicity of infection
MOPS 4-Morpholine-propanesulfonic acid
OD Optical density
PFA Paraformaldehyde
p.f.u. Plaque forming unit
PIPES 1,4-Piperazinediethanesulfonic acid
rpm rounds per minute
SDS Sodium dodecyl sulfate
TAE Tris-acetate-EDTA buffer
TE Tris-EDTA buffer
TEMED N, N, N‘, N‘-Tetramethylethylendiamine
TGN trans Golgi network
TNE Tris-NaCl-EDTA buffer
VV Vaccinia virus
25
wt Wild type
3.2 Buffers and solutions
All the solutions used for cell culture were sterilized (autoclaved or filtered with 0.2 mm filters).
Ampicillin stock
100 mg/ml ampicillin
Ampuwa H2O
stored at –20°C
Cellular lysis buffer for Western Blot 5x
250m; Tris/HCl pH 6.8
10% SDS
7.5% Glycerin
12.5% 2-Mercaptoethanol
0.5% Bromophenol blue
DNA loading buffer 6x
0.25% bromophenol blue
40% (w/v) sucrose in water
Fixing solution 1 for EM
8% PFA
0.2M PHEM
0.2% glutaraldehyde
Fixing solution 2 for EM
8% PFA
0.1M PHEM
Glutaraldehyde 25% (EM grade)
25% glutaraldehyde
dissolved in A.dest.
Paraformaldehyde 16%
16% PFA
dissolved in A.dest. with 0.16% Na2CO3 at 80°C
stored at –20°C
PBG buffer (PBS-BSA-Gelatine)
1% FSG (fish skin gelatine)
0.8% BSA in 20 mM glycine
dissolved in PBS
stored at –20°C
PHEM buffer 0.4M pH6.9 (PIPES-HEPES-EGTA-MgCl2)
240 mM PIPES
100mM HEPES
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8mM MgCl2
40mM EGTA
adjusted pH to 6.9 with KOH
stored at –20°C
Phosphate buffered saline (PBS) pH 7.4
140mM NaCl
5.4mM KCl
9.7mM Na2HPO4x2H2O
2mM KH2PO4
Aqua bidest.
Protein loading buffer 5x
250mM Tris pH 6.8
10% SDS
7.5% Glycerine
0.5% bromophenol blue
12.5% 2-Mercaptoethanol
SDS-electrophoresis running buffer 10x
0.25M Tris Base
0.192M Glycine
1% SDS
SDS-electrophoresis transfer buffer 10x
0.25% Tris Base
0.192M Glycine
SDS-electrophoresis washing buffer 5x pH 7.5
0.25M Tris Base
0.75M NaCl
0.25 vol.% Tween 20
adjust to pH 7.5 with HCl
SDS-protein running gel 10%
A.dest. 4.0 ml
30% acrylamide mix 3.3 ml
1.5M Tris pH 8.8 2.5 ml
10& SDS 0.1 ml
10% APS 0.1 ml
TEMED 0.004 ml
SDS-protein stacking gel 5%
A.dest. 3.4 ml
30% acrylamide mix 0.83 ml
1M Tris pH 6.8 0.63 ml
10% SDS 0.05 ml
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10% APS 0.05 ml
TEMED 0.005 ml
Stripping buffer for WB
100mM 2-Mercaptoethanol
2% SDS
62.5mM Tris/HCl pH 6.7
TAE buffer 50x pH 8.0
2M Tris-acetate
0.5M NaCl
50mM EDTA
TE buffer
10mM Tris/HCl
1mM EDTA
TMN buffer (Tris-MgCl2-NaCl)
0.01M Tris pH 7.5
1.5mM MgCl2
10mM NaCl
TNE buffer pH 7.4
40mM Tris/HCl
1mM EDTA
150mM NaCl
3.3 Media
RPMI 1640 Medium with Glutamax-1 GibcoBRL, Karlsruhe
MEM (Minimal Essential Medium) GibcoBRL, Karlsruhe
Dulbecco’s MEM with Glutamax-1, Sodium Pyrovate
4500 mg/l glucose, pyridoxine GibcoBRL, Karlsruhe
OptiMem GibcoBRL, Karlsruhe
Lactalbumin Hydrolysate 10% Solution GibcoBRL, Karlsruhe
BMS (Basalmedium Supplement) Biochrom KG, Berlin
Trypsin-EDTA (1x)
in HBSS w/o CA&MG W/EDTA 4N1 GibcoBRL, Karlsruhe
Antibiotics-Antimycotics prepared with
10000 U/ml penicillin G sodium
10000 mg/ml streptomycin sulfate
25 mg/ml amphotericin B in 0.85% saline GibcoBRL, Karlsruhe
Fetal calf serum (FCS) GibcoBRL, Karlsruhe
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3.4 Antibodies
rabbit serum a-VV Sigma, Taufkirchen
rabbit serum a-CDV.H provided by Ricardo Witteck, Lausanne
rabbit serum a-B5R provided by Ricardo Witteck, Lausanne
MAb a-B5R provided by Gerhard Hiller (Schmelz et al., 1994)
MAb a-A17L directed against the N-terminus of A17L
Goat anti rabbit HRP Dianova, Hamburg
Goat anti rat FITC Dianova, Hamburg
Phalloidin/rhodamine Sigma, Taufkirchen
3.5 Cells
CEF primary chicken embryo fibroblasts
BHK –21 baby hamster kidney (ATCC CCL-10)
RK-13 rabbit kidney (ATCC CCL-37)
BSC-40 african green monkey kidney (provided by Stewart Shuman, New York)
3.6 Viruses
Vaccinia virus strain MVA (cloned isolate F6) (Mayr, 1975)
Virus from the 582nd CEF passage was used for this study
MVA-ssP-K1L-gfp (Staib et al., 2000)
WR
IHD-J
3.7 Oligonucleotides
(used as primers)
NIH-GS83: 5‘-GAATGCACATACATAAGTACCGGCATCTCTAGCAGT-3‘
IIIfl1b: 5‘-CACCAGCGTCTACATGACGAGCTTCCGAGTTCC-3‘
II 0011b-3‘: 5‘-CGTCGTTTAAACATATGACTAGGGACC-3‘
II 0011b-5‘: 5‘-CGTTGTATACACATATTGAGTTGTCTG-3‘
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4. METHODS
4.1 Bacterial techniques
4.1.1 Transformation of bacteria with plasmid DNA
Two different protocols were used for bacterial transformation. Electroporation was performed
to transform electrocompetent DH10B cells with newly made plasmids immediately after
ligation, and heat shock protocol for transformation of HB101 cells with purified plasmid DNA.
4.1.1.1 Preparation of electrocompetent cells
A single bacterial colony was inoculated in 10 ml of LB medium in a small glass tube and
incubated O/N at 37°C shaking. The next morning the O/N culture was inoculated in 200 ml
LB medium in a 1 l flask, and the cells were grown until an OD600 of 0.5 was reached (about 2
h shaking at 180 rpm). The cells were cooled on ice, transferred into Beckmann centrifuge
tubes, and centrifuged for 15 min at 4200xg in a precooled GS-3 rotor at 4°C. The cell pellets
were washed first in 200 ml ice-cold and sterile Ampuwa water, then in 100 ml Ampuwa water
and finally resuspended in 10 ml cold 10% glycerol (filtered). Cells were spun down for 10 min
at 4200xg, resuspended in 600 ml of cold 10% glycerol, aliquoted (50 ml/sterile Eppendorf
tube), frozen and stored at –80°C.
4.1.1.2 Electrotransformation
For electroporation DH10B cells and the mixture samples obtained after the ligation reaction
were thawed on ice. 5 ml of the ligation mixture (out of 20 ml) were added to 25 ml of DH10B
cells and 10 ml A. dest. and mixed. The cells and the DNA were incubated on ice for some
minutes and introduced to an ice-cold electroporation cuvette. The cells were shocked by 1
pulse of 1.8 kV in 3-4 msec. Immediately after the pulse 1 ml of RT SOC medium was added
and the suspension was transferred into a glass tube, then incubated at 37°C for 60-90 min
shaking. 100 m l of suspension was plated on prewarmed LB/Amp plates (100 mg/ml
ampicillin) and incubated at 37°C O/N.
4.1.1.3 Heat shock transformation
HB101 cells were thawed on ice, and aliquots of 100 ml for each transformation were
transferred into prechilled 15 ml Falcon 2059 polypropylene tubes. 1 ng of transforming
plasmid DNA was added to the cells, mixed gently and incubated on ice for 30 min. The cells
were heat shocked for 45 sec. at 42°C in a water bath. The cells were immediately transferred
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on ice and incubated for 2 min. 1 ml of RT SOC medium was added to each tube. The tubes
were incubated at 37°C for 1 h by shaking at 260 rpm. 200 ml of the cell suspension was
spread on prewarmed LB/Amp plates (100 mg/ml ampicillin)  and incubated O/N at 37°C.
4.1.2 Plasmid DNA isolation from E.coli
4.1.2.1 Qiagen maxi preparation
The plasmids used in the transfection experiments and the generation of recombinant MVA
were prepared with the Qiagen maxiprep kit, according to the manufacturer’s instructions.
Qiagen plasmid purification protocols are based on a modified alkaline lysis procedure,
followed by adsorption of plasmid DNA to Qiagen anion-exchange resin under appropriate
low-salt and pH conditions. RNA, proteins, dyes, and low-molecular-weight impurities are
removed by a medium-salt wash. Plasmid DNA is eluted in a high-salt buffer, concentrated
and desalted by isopropanol precipitation.
Briefly, plasmids were prepared from E.coli DH10B or HB101 bacterial cultures grown in the
presence of the selective antibiotic ampicillin. A single colony was inoculated into 3 ml of
standard LB medium in the presence of ampicillin (100 mg/ml), and grown O/N at 37°C with
vigorous shaking (260 rpm). The miniculture was diluted 1:500 into a larger volume of
selective medium and grown to saturation (O/N) at 37°C with gently shaking (100 rpm).
The bacterial cells were harvested and centrifuged at 4200xg for 10 min at RT in a Beckman
Avanti J-25 Centrifuge using a JA-10 rotor. The pellet was resuspended in 10 ml ice-cold
buffer P1 containing RNaseA (1 mg/10 ml) and transferred into appropriate tubes for the JA
25.50 rotor. 10 ml of buffer P2 were added, mixed gently, and the mixture was incubated at
RT for less than 5 min. 10 ml of ice-cold buffer P3 was added, mixed gently, and the mixture
incubated on ice for 20 min. The suspension was centrifuged at 25000xg for 30 min at 4°C.
The supernatant was transferred into a new tube and the centrifugation was repeated under
the same conditions. The Qiagen column was equilibrated with 10 ml buffer QBT.
Subsequently, the supernatant from the cell lysate was applied to the column. Plasmid DNA
bound to Qiagen anion-exchange resin was washed twice with 30 ml buffer QC and eluted
with 15 ml buffer QF, and collected into another centrifugation tube. The DNA was
precipitated with 0.7 vol of isopropanol, incubated 5 min at RT and centrifuged at 25000xg for
30 min at 4°C. The DNA  pellet was washed with 70% ethanol, centrifuged for 10 min at
25000xg, dried and dissolved in 300-500 ml 1xTE buffer. The DNA was stored at –20°C.
4.1.2.2 Qiagen mini preparation
This procedure, which isolates rapidly plasmid DNA from bacteria using the alkaline lysis
method followed by ethanol precipitation, was used during the cloning process to isolate small
amounts of DNA from a large number of colonies. The cells are disrupted by treatment with
detergents and osmotic shock, followed by the alkaline denaturation of the nucleic acids. The
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renaturation of the nucleic acids occurs at low pH. Chromosomal E.coli DNA renatures
intermolecularly, leading to a high molecular network structure, whereas the plasmid DNA
because of the topological form of its single DNA strands renatures intramolecularly. Proteins
are denatured by SDS. Cellular debris, denatured proteins and chromosomal DNA are
separated from plasmid DNA and RNA by centrifugation.
Briefly, each single colony was inoculated into 3 ml of LB medium (plus 100 mg/ml ampicillin)
in glass tubes and grown O/N at 37°C with vigorous shaking (260 rpm). The next day 1.5 ml
of the miniculture were transferred into Eppendorf tubes, and the bacterial cells were pelleted
at 4000xg for 5 min in a benchtop centrifuge. The pellet was resuspended in 100 ml of ice-cold
buffer P1 containing RNaseA and incubated at RT for 5 min. 200 ml of buffer P2 was added,
mixed gently, and the mixture was incubated at RT for 2-3 min. 150 ml of ice-cold buffer P3
was added and mixed gently. The mix was incubated on ice for 5-10 min and then centrifuged
at 10000xg for 10 min. The supernatant was transferred in a new Eppendorf tube containing 1
ml ice-cold EtOH and 10 ml 3M NaAc. The suspension was vortexed, incubated on ice for 20
min, and centrifuged for 20 min at 10000xg and 4°C. The pellet was washed with 300 ml of
70% EtOH, spun down at 10000xg for 3 min, air dried for about 30 min and dissolved in 50 ml
destilled water. The DNA was stored at –20°C.
4.2 DNA techniques
4.2.1 In vitro modification and recombination of DNA
4.2.1.1 Preparation of vectors and inserts by digestion with restriction enzymes
The fragmentation of DNA with restriction enzymes is a common method to obtain DNA
targets to generate new plasmids by in vitro recombination. Restriction endonucleases are
enzymes, which recognize specific dsDNA-sequences and cleave both strands. Three types
of restriction endonucleases are known. Type II restriction enzymes are most valuable for
gene manipulation and cleave the duplex at specific target sites. Those are generally between
4 and 8 bp of length and very specific. After the cleavage 5‘-phosphorylated and 3‘-
hydroxylated ends are originated. In principle each restriction enzyme needs its individual
reaction conditions for hydrolysis, which are given by the manufacturer. If two or more of the
needed restriction endonucleases require the same conditions, the DNA can be fragmented
with a mixture of these enzymes. The typical reaction was performed in 20-50 ml total volume,
using 2-10 mg DNA and 5-10 U restriction enzyme in the appropriate conditions (buffers and
temperature) for 2-3 hours. The enzyme was inactivated by heating to 65°C for 10 min.
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4.2.1.2 Enzymatic in vitro amplification of DNA by Taq-polymerase
The polymerase chain reaction (PCR) allows to amplify a selected DNA sequence in vitro.
The synthesis starts at two primers flanking the DNA sequence of interest. The PCR is carried
out in thermocyclers and consists generally of 3 steps. Each parameter has to be optimized
according to the individual template-primer combination.
The initial denaturation of dsDNA at 94°C follows the sequence specific annealing of the
primers at 45-65°C. Finally the thermostable DNA polymerase (temperature optimum at 72-
74°C) starts the synthesis of new DNA at the 3‘-OH ends of both primers that are hybridized
to the DNA template. This cycle is repeated 20-35 times. A final incubation at 72°C for 2-7
min allows to finish the synthesis of incomplete DNA amplificates.
4.2.1.3 Dephosphorylation of 5‘ ends of DNA fragments with alkaline
phosphatase
To avoid religations of linearized vectors, the 5‘-phosphate of the DNA is removed to create
free 5‘-hydroxylated ends. For this 10-50 pmol DNA were incubated for 1 h at 37°C in the
presence of 1 U alkaline phosphatase in the appropriate dephosphorylation buffer. The
enzyme was inactivated by incubation at 65°C for 1 h after adding 1/10 volume 50 mM EDTA.
4.2.1.4 Creation of blunt ends by T4 DNA-polymerase or Klenow enzyme
To ligate DNA fragments lacking compatible ends the sticky ends need to be blunted. Klenow
enzyme catalyzes the polymerization of DNA at the short hydroxylated ends in the presence
of dNTPs. Therefore, 5‘-overhangs of ssDNA can be filled in to create double stranded blunt
ends. The typical reaction was performed for 30 min at 30°C in 1x PCR buffer in a total
volume of 100 ml using 1U Klenow enzyme and 0.1 pmol dNTPs. The enzyme was inactivated
at 65°C for 30 min.
T4 DNA-polymerase has a very active single strand specific 3‘-5‘-exonuclease activity in the
absence of dNTPs, removing therefore the 3‘-overhangs of ssDNA. The reaction was
performed in 1xT4 reaction buffer in a total volume of 50 ml for 30 min at 37°C.
4.2.1.5 Ligation of DNA fragments by T4 DNA-ligase
The DNA-ligase of bacteriophage T4 catalyzes the phosphodiester binding between
neighboring 3‘-hydroxylated and 5‘-phosphorylated ends of dsDNA. 1U of this enzyme is
defined as the amount necessary to catalyze the conversion of 1nmol 32Pi in ATP at 37°C in
20 min (Weiss-Unit).
In this work all ligations were performed in 1xT4 ligation buffer using 1 ml T4 DNA-ligase (Life
Technologies) in a total volume of 15 ml. Generally 50-200 ng of vector DNA were incubated
with insert DNA (molar ratio of vector to insert 1:2-5) at 14°C overnight. The sample volume
was filled up with A.dest. to 50 ml, and the T4-DNA ligase was inactivated at 70°C for 10 min.
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For electroporation the DNA was precipitated with 500 ml butanol, air-dried and dissolved in
20 ml A.dest.
4.2.2 Purification of nucleic acids
4.2.2.1 Removal of proteins by phenol/chlorophorm extraction
Nucleic acid solutions containing a high amount of proteins or enzymes, which are difficult to
inactivate (e.g. RNaseA) need to be purified by phenol extraction.
The DNA solution was mixed with the same volume of phenol/chlorophorm (1:1) and
centrifuged for 2 min at maximum speed in a benchtop centrifuge. The upper water phase
containing the DNA was removed carefully and re-extracted if necessary (for instance if a
visible interphase of denatured proteins was present). For further use of the DNA the phenol
has to be removed by extraction with chlorophorm/isoamylethanol (24:1, same volume).
Subsequently, the DNA was precipitated and eluted in an appropriate amount of 1xTE buffer.
4.2.2.2 Concentration of nucleic acids by ethanol precipitation
Solutions with a low concentration of nucleic acids can be concentrated by ethanol
precipitation. The DNA solution was mixed with 1/10 volume of 3M NaAc and 2.5-3 volumes
of ice-cold ethanol and incubated on ice for 20 min. The nucleic acids then precipitate as
sodium salts. The samples were centrifuged in a precooled benchtop centrifuge for 15 min at
12000xg and 4°C. The pellet was washed with 70% ethanol and air dried for 30 min or in a
„speed-vac“ concentrator for 1-2 min. The DNA was eluted in an appropriate volume of 1xTE
buffer or water.
4.2.2.3 Photometric estimation of purity and concentration of nucleic acids
According to the law of Lambert-Beer the concentration of a solution is directly proportional to
its extinction or absorption.
To determine quality and yield, the DNA was measured in an UV spectrophotometer
(Pharmacia Biotech) at 260 nm (absorption maximum of nucleic acids) and 280 nm
(absorption maximum of proteins), normally diluted 1:50 in destilled water. The nucleic acid
concentration was calculated by the spectrophotometric conversions:
dsDNA 1 OD260 = 50 mg/ml
ssDNA 1 OD260 = 40 mg/ml
ss oligonucleotides 1 OD260 = 30 mg/ml
In addition the ratio A260/A280 was measured, which should be 1.7-1.9 for protein free solutions
of nucleic acids.
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4.2.2.4 Isolation of DNA fragments from agarose gels (silica adsorption)
The DNA band was excised from the agarose gel with a clean, sharp scalpel. The gel slice
was minimized in size by removing excess agarose and weighed. 3 volumes of buffer QX1
were added to 1 volume of gel for DNA fragments of 100 bp to 4 kb. For DNA fragments > 4
kb 2 volumes of water were added additionally. The silica matrix was resuspended by
vortexing for 30 sec and added according to the DNA amount:
< 2 mg DNA 10 ml of Qiaex II
2-10 mg DNA 30 ml of Qiaex II
each additional 10 mg DNA add additional 30 ml of Qiaex II
This mixture was incubated at 50°C for 10 min with occasionally mixing to keep the silica
matrix in suspension. This allows the release of DNA from the melting agarose and
adsorption to the silica matrix. Since the adsorption is only efficient at pH < 7.5, those
conditions need to be checked and if necessary adjusted by adding of 10 ml 3M sodium
acetate, pH 5.5, followed by an incubation at RT for further 10 min. The sample was
centrifuged for 30 sec and the supernatant removed carefully with a pipet. The pellet
containing the DNA was washed once with 500 ml buffer QX1 to remove residual agarose
contaminations and twice with 500 ml buffer PE to remove residual salt contaminations. The
pellet was air-dried for 30 min until it became white. The DNA was eluted in 20 ml water by
vortexing the pellet and incubation according to the size of the DNA fragments:
DNA fragments < 4 kb RT for 5 min
DNA fragments 4-10 kb 50°C for 5 min
DNA fragments > 10 kb 50°C for 50 min
The sample was centrifuged for 30 sec at 10000xg in a benchtop centrifuge and the
supernatant, containing the purified DNA, was pipeted into a clean Eppendorf tube and stored
at –20°C.
4.2.2.5 Purification of PCR products
After the PCR procedure, surplus nucleotides, primers and enzymes have to be separated
from the PCR product. This is possible by using a commercial available kit (e.g. Qiagen PCR
purification kit) or by loading the sample to an agarose gel and recovering the DNA as
described above.
4.2.3 Analysis of plasmid DNA
4.2.3.1 Restriction analysis
Fragmentation of DNA by restriction enzymes can be used to check the insertion and
orientation of a foreign gene in the plasmid vector after cloning. Preferably one or two
enzymes were chosen, cutting once in the insert and once in the vector, leading to DNA
fragments easily distinguishable in size.
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Analysis of plasmid DNA obtained after mini or maxi preparation was carried out in a total
volume of 10-20 ml, using 2.5-5 U enzyme in the appropriate buffer. After incubation for 1 h
the sample was loaded to an agarose gel for further analysis.
4.2.3.2 Analysis by horizontal agarose gel-electrophoresis
Agarose, which is extracted from seaweed, is a linear polymer, that forms a matrix upon
hardening after boiled up in a desired buffer. When an electric field is applied across the gel,
DNA, which is negatively charged at neutral pH, migrates towards the anode. The rate of
migration is determined by the molecular size of the DNA, the agarose concentration, the
conformation of the DNA, the applied voltage and the composition of the electrophoresis
buffer. The paracristalline mesh system of agarose gels allows the separation of high
molecular DNA. The density is dependent on the agarose concentration, varying between 0.5
and 2.5%. For resolution of linear dsDNA fragments of 0.5-10 kb an agarose concentration of
1% is recommended.
The agarose was dissolved in 1xTAE buffer by boiling. After cooling down to 50-60°C,
ethidium bromide  was added to a final concentration of 0.5-1 mg/ml and thoroughly mixed.
The solution was poured into a gel chamber, a comb was introduced to create the slots, and
the gel left to polymerize. After the gel was completely set it was mounted into the
electrophoresis tank and covered with 1xTAE buffer. DNA samples mixed with DNA gel-
loading buffer were introduced into the slots of the submerged gel. A voltage of 5-10 V/cm
was applied for the requisite time.
Ethidum bromide intercalates with the DNA and can be detected by ultraviolet light (250-360
nm). The minimum amount of DNA that can be detected by photography of ethidium-bromide-
stained gels is about 20 ng in a 0.5 cm wide band.
4. 3 Analysis of proteins
4.3.1 Discontinous denaturating PAA-gel electrophoresis (SDS-PAGE)
Proteins are composed of different amino acids and do not have a constant ratio of mass and
charge. By heating up the proteins, the three dimensional structure unfolds and the highly
ionic detergent SDS can bind, making all proteins irrespective of their amino acid composition
negatively charged. Because the amount of SDS bound is almost always proportional to the
molecular weight of the polypeptide and is independent of its sequence, SDS-polypeptide
complexes migrate through polyacrylamide gels in accordance with the size of the
polypeptide. Modifications to the polypeptide backbone, such as N- or O-linked glycosylation,
however, have a significant impact on the apparent molecular weight. Thus, the apparent
molecular weight of glycosylated proteins is not a true reflection of the mass of the
polypeptide chain.
Polyacrylamide gels are composed of chains of polymerized acrylamide that are cross-linked
by a bifunctional agent. The effective range of separation depends on the concentration of
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polyacrylamide used to cast the gel and on the amount of cross-linking. Cross-links formed
from bisacrylamide add rigidity and tensile strength to the gel and form pores through which
the SDS-polypeptide complexes must pass. The SDS-polypeptide complexes in the sample
that is applied to the gel are swept along by a moving boundary created when an electric
current is passed between the electrodes.
To obtain sharp protein bands, the gel is composed of a stacking gel (5%, pH 6.8) and a
resolving gel (6-15%, pH 8.8). The chloride ions in the sample and in the stacking gel form the
leading edge of the moving boundary, and the trailing edge is composed of glycine molecules.
Between the leading and the trailing edges of the moving boundary is a zone of lower
conductivity and steeper voltage gradient which sweeps the polypeptides from the sample
and deposits them on the surface of the resolving gel. There, the higher pH of the resolving
gel favors the ionization of glycine, and the resulting glycine ions migrate through the stacked
polypeptides and travel through the resolving gel immediately behind the chloride ions. Freed
from the moving boundary, the SDS-polypeptide complexes move through the resolving gel in
a zone of uniform voltage and pH and are separated according to size by sieving.
The samples were prepared by heating them in 1x SDS gel-loading buffer to 95°C for 10 min
to denature the proteins and a brief sonication to shear the DNA. The gel was placed in a
vertical position into the electrophoresis tank and the samples loaded into the wells. A voltage
of 8 V/cm was applied to the gel. After the dye front had moved into the resolving gel, the
voltage was increased to 15 V/cm, and the gel ran until the bromophenol blue front reached
the bottom of the resolving gel.
4.3.2 Identification of proteins by immunoblotting (Western blotting)
Western blotting is a useful method for the identification and quantitation of specific proteins
in complex mixtures of proteins that are not radiolabeled. Because electrophoretic separation
of proteins is almost always carried out under denaturing conditions, any problems of
solubilization, aggregation and coprecipitation of the target protein with adventitious proteins
are eliminated. Antibodies react specifically with antigenic epitopes displayed by the target
protein attached to the solid support.
After separating the proteins by SDS-polyacrylamide gel electrophoresis according to their
molecular weight, they were transferred to a nitrocellulose membrane (BioRad) using a Semi-
dry Electroblotter (Sartorius). In the electric field the negative charged proteins migrate
towards the anode, leaving the gel and meeting the PVDF-membrane, where they hold on via
hydrophobic and electrostatic interactions.
Whatman 3MM paper and the nitrocelulose membrane were cut to the size of the resolving
gel. Whatman paper, membrane and PAA resolving gel were soaked in 1x transfer buffer and
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sandwiched in the blotting apparatus as follows:
+ anode +
3 MM Whatman paper
PVDF-membrane
PAA-resolving gel
3MM Whatman paper
- cathode -
The components have to fit tightly to each other, without introducing bubbles. The transfer
occurred in 1 h 30 min at 150 mA, maximum 20 V (mA = cm2 of membrane x 0.8).
The immobilized proteins on the membrane can be detected by immunological methods. First
the membrane was blocked in 1x washing buffer (see 3.2) containing 1% BSA  for 1 h at RT
or at 4°C O/N. The primary antibody was diluted in blocking buffer and incubated with the
membrane for 1.5 h at RT with continuous agitation. The membrane was washed 3x with
washing buffer, then the secondary antibody (horseradish peroxidase conjugated), directed
against the Fc-part of the primary antibody, was incubated with the membrane in blocking
buffer for 45 min. After washing the membrane 3x with washing buffer Lumi-Light Western
Blotting Substrate (Roche) was added and incubated for 5 min, rocking.
The chemiluminescence reaction results in the emission of photons (wavelength 425 nm),
which are detectable by X-ray films. The exposure time to the film is dependent of the signal
intensity. 10-50 pg antigen are detectable with this method.
4.3.3 Stripping of the Western Blot
Substrate and antibodies can be stripped off the membrane, and the blot can be reused for
further Western blot analysis.
The membrane was incubated for 1 h at 50°C in stripping buffer (see 3.2) and washed 2x for
10 min in PBS.
The membrane is now ready to start with a new immunoblotting procedure, beginning with
blocking procedure as described above.
3.3.4 Quantification of proteins
The determination of total protein can be carried out in a UV spectrophotometer, measuring
the absorbance at 260 and 280 nm. The concentration of proteins (C) can be calculated as
follows:
C (mg/ml) = 1.55 A280 – 0.76 A260
Another common method is the determination using the bicinchoninic acid (BCA) kit from
Pierce according to the manufacturer’s instructions. This system combines the biuret reaction
(proteins reducing Cu2+ in an alkaline medium to produce Cu+) with the highly selective
detection reagent BCA. BCA in the form of its water-soluble solution salt, is a sensitive, stable
and highly specific reagent for the cuprous ion and forms a complex BCA-Cu+-BCA, exhibiting
a strong absorbance at 562 nm. Dilutions in TMN buffer (for samples obtained after CsCl
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gradient purification) for a series of 8 calibration standards using a BSA stock solution of 2
mg/ml were prepared, sufficient for a working range of 20-2000 mg/ml. The reaction was
carried out in microtiter plates. 25 ml of each standard, TMN buffer (blank) or samples were
pipeted into the appropriate microwell plate wells. 200 ml of the working reagent (50 parts of
reagent A mixed with 1 part of reagent B) were added to each well, and the plate was
incubated at 37°C for 30 min. The absorbance was measured using a microelisa plate reader
(BioRad) at 570 nm. A standard curve was prepared by plotting the absorbance values
obtained on the x-axis against the specific standard protein concentrations on the y-axis,
performing linear regression analysis with Microsoft Excel 5.0. Using the standard curve, the
protein concentration for each unknown protein sample was determined.
4.4 Cell culture techniques
4.4.1 Host cells for in vitro cultivation of MVA
MVA grows efficiently in avian cells and baby hamster kidney cells (BHK21). After introducing
the Vaccinia Virus specific K1L gene into the genome of MVA as a selection marker, this
recombinant MVA is able to multiply in rabbit kidney cells (RK13).
4.4.1.1 Preparation of chicken embryo fibroblasts (CEF)
Since MVA was generated on primary chicken embryo fibroblasts, those cells were used
mostly in this work. CEFs were prepared weekly using 20 chicken embryos (9-11 days old):
The upper part of the fertilized eggs was cleaned with 70% ethanol and opened with a sterile
scissor. The embryos were drawn out with a sterile forceps, decapitated and transferred to a
dish containing sterile PBS. Legs and inner organs were removed. The embryos were
collected into a 20 ml syringe without a needle and squeezed into an Erlenmeyer flask
containing 200 ml PBS, where the cell clumps sedimented. After 1 min the supernatant was
discarded, and the cells washed again with 200 ml PBS. Cell aggregates were disturbed by
quick magnetic stirring for 25 min in the presence of 50 ml Trypsin. The suspension was
filtered carefully through 2 layers of sterile mesh (avoiding to pour cell clumps on the mesh).
For the remaining cell clumps in the Erlenmeyer flask this step was repeated once or twice,
using 25 ml Trypsin each. The filtrate was filled up with PBS to 300 ml, distributed  into six 50
ml Falcon tubes and centrifuged for 7 min at 500xg and 4°C in a Heraeus swing out
centrifuge. The supernatant was discarded and the pellet resuspended well in 10 ml PBS with
a 10 ml pipet. The suspension was  filled up with PBS to 50 ml total volume per Falcon tube
and centrifuged as before. This washing step was repeated twice to remove the Trypsin. The
pellets were pooled and resuspended in 10 ml medium (MEM containing 10% Lactalbumin,
5% BMS and 1% Antibiotics/Antimycotics). 50 ml medium was added and the cell suspension
was filtered again through 2 layers of mesh to remove remaining cell clumps. Those cells
were then introduced into 2 l medium and distributed into T225 flasks, using 40-50 ml per
flask. The cells were incubated at 37°C and 5% CO2 and should be confluent within 3-4 days.
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It is possible to obtain at least a first passage of very good cell quality by splitting them 1:5 -
1:10. Primary CEFs with a subconfluent monolayer can „rest“ at 30°C for one week and then
be used for the first passage, still having a very nice cell quality. Generally CEFs were
prepared freshly.
4.4.1.2 Cell culture techniques for BHK21 and RK13 cells
BHK21 and RK13 are adherent cells. The growth by cell division is inhibited by contact with
neighboring cells, leading to a confluent monolayer.
The cells were maintained under standard cell culture conditions using RPMI1640. The media
were supplemented with 1% antibiotic-antimycotic solution and 10% fetal calf serum (FCS,
inactivated for 30 min at 56°C) for RK13 cells and 7% FCS for BHK21 cells respectively. The
cells were kept in culture for serial passages (maximum 50), and were expanded 1:5 – 1:10
twice weekly by trypsinization. The old medium was removed from the cells and the
monolayer washed with PBS. Trypsin-EDTA solution was introduced according to the growth
area and the number of cells (e.g. 5 ml for a T185 cell culture flask, ª 2x107 cells) and
incubated for 1-2 min for BHK21 and 10-15 min at 37°C for RK13 respectively, until the cells
detached from the bottom of the flask. The cells were resuspended in media and distributed
into new cell culture flasks in the appropriate amount of media (e.g. 25-30 ml for T185).
For long time storage in liquid nitrogen (-196°C) the media of a T25 flask was removed, the
cells washed with PBS and the confluent monolayer treated with 2-3 ml Trypsin/EDTA as
described above. The cells were transferred into a 15 ml Falcon tube and pelleted for 5 min at
500xg. The supernatant was removed and the pellet resuspended in 1.5 ml FCS. RPMI1640
with the recommended amount of FCS and 20% DMSO was added and mixed gently. The
cells were aliquoted into cryovials (1 ml each vial), incubated for 10 min on ice, stored for 1-2
days at –80°C and then transferred into liquid nitrogen for long term storage.
To take the frozen cells in culture, the cryovials were warmed up to 37°C as quick as
possible. Immediately after the freezing medium was thawed, the cells were introduced into
10 ml prewarmed RPMI1640 containing the recommended amount of FCS, and pelleted at
500xg for 5 min. The cell pellet was resuspended in medium, transferred to a T25 cell culture
flask and incubated at 37°C and 5% CO2.
4.4.2 Amplification of Vaccinia Virus
The amplification of MVA to generate working stocks (crude stocks) can be carried out on
CEF and BHK21.
Ten T185 cell culture flasks with subconfluent monolayers of CEF or BHK21 cells were
infected with a m.o.i. of 0.1-1 p.f.u. in 10 ml medium per flask with occasional shaking. After 1
h 15 ml medium per flask were added. The cells were kept in the incubator until lysis (36 h for
m.o.i. of 1, 2-3 days for m.o.i. of 0.1). During the infection the cells round up and finally
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detach. The cells were harvested by scraping them off from the bottom of the flask and
transferred into centrifuge tubes. After a centrifugation for 15 min at 4°C and 3500xg, the
pellet was resuspended in 1 ml medium without supplements per flask, obtaining 10 ml virus
suspension in total. The virions inside the cells were released by disrupting the cells. This was
done by 3 cycles of freeze-thawing using dry ice and a 37°C water bath, vortexing vigorously
after the thawing. Those crude stocks were stored at –80°C and sonicated briefly before use.
Virus stocks of WR and IHD-J, respectively were generated by infection of HeLa cells with a
m.o.i. of 0.1. Intracellular virus was isolated and semi-purified at 3 days post infection as
described elsewhere (Pedersen et al., 2000).
4.4.3 Determination of infectivity
4.4.3.1 Titration of MVA (TCID50)
To determine the titer of a virus suspension subconfluent monolayers of BHK21 or CEF cells
in 96-well plates were infected with different dilutions. To avoid aggregations of virus particles,
the suspension was sonicated 3 times for 1 min in ice water, followed by vigorous vortexing.
The homogenous virus suspension was diluted in log10 steps, usually beginning with 10
-2. 100
ml virus dilution was added to 100 ml medium on top of the cells into 8 wells per dilution. The
cells were incubated for 5 days at 37°C and 5% CO2. The titer was calculated by the number
of wells showing a cytopathic effect (CPE) of the cells according to the method of Spearman
& Kaerber:
First the log10 of the dilution where 50% of the wells show an infection was determined:
log10 = x - d/2 + (dSr/n)
x = highest dilution with all 8 wells showing a CPE
d = log10 of the dilution factor (d = 1 for 10 fold dilutions)
r = number of positive wells per dilution
n = total number of wells per dilution (here: n = 8)
The reverse value resulting of this formula is the virus titer referred to the infectious dose per
unit volume, in this case TCID50/0.1 ml, because the cells were infected with 100 ml virus
dilution per well. The virus titer, given in TCID50/ml can be calculated.
4.4.3.2 Titration of MVA by immunostaining
MVA was plaque titrated on CEFs grown in 6-well plates infected with 10 fold serial dilutions
of the virus. Cells were fixed at 24 h.p.i. with a 1:1 mixture of methanol:acetone, and the virus
detected with a rabbit serum against Vaccinia Virus (Sigma) in a dilution of 1:500 – 1:1000.
The procedure is described in detail in 4.5.4.2. With this procedure the plaque forming unit/ml
was calculated.
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4.4.3.3 Titration of WR and IHD-J by cristal violet staining
WR and IHD-J were plaque titrated on BSC-40 cells by infecting monolayers with 10 fold
serial dilutions of the virus. Cells were fixed and plaques visualized 24 h.p.i. with a mixture of
0.2% crystal violet and 3% formaldehyde in PBS. Living cells incorporate the crystal violet and
obtain a dark blue color, whereas dead cells do not. With the number of white plaques on a
blue monolayer the plaque forming unit/ml is calculated.
4.4.4 Plasmid-DNA transfection of infected adherent cells
Different methods and kits for transfection of DNA into eukaryotic cells are commercially
available. In this work LipofectAmine Plus Reagent (Life Technologies) was used.
4.4.4.1 Stable transfection for generation of recombinant MVA
The generation of recombinant vaccinia viruses requires a stable insertion of the foreign DNA
into the virus genome. Infection of the cells with a low m.o.i. of virus and transfection with a
surplus of plasmid DNA increases the possibility to generate recombinants. The plasmids
used in this work were constructed to allow homologous recombination of the gene of interest
into the MVA genome. Those genes are subjected to transcriptional control of vaccinia virus
specific promotors.
CEF or BHK21 cells were grown in 6 well plates to 80% confluence. The medium was
removed and replaced by a virus dilution with a moi of 0.05-0.1 p.f.u. in 800 ml serum-free
OptiMem per well. The cells were incubated for 1.5 h at 37°C and 5% CO2 with occasional
shaking. Meanwhile the transfection reagents were prepared:
Mix A: 15 mg Plasmid DNA were pre-complexed with 15 ml Plus reagent in 200 ml serum-free
OptiMem for 15 min at RT.
Mix B: 15 ml LipofectAmin reagent were mixed with 200 ml serum-free OptiMem.
Mix A and B were combined, mixed and incubated for 15 min at RT. DNA-LipofectAmin
complexes are now forming.
The infection-medium was removed from the cells, and the monolayers washed twice with
serum-free prewarmed OptiMem.
The transfection mix was added to each well containing 555 ml OptiMem, reaching a total
volume of 1 ml per 6 well. The complexes were mixed gently into the medium and incubated
at 37°C and 5% CO2 over night. The next day, the transfection mix was replaced by 2 ml
complete medium and incubated for another day. The cells were harvested by scraping them
off with a rubber policeman in 1-1.5 ml medium and frozen at –80°C.
4.4.4.2 Transient transfection
Detection of protein expression and protein localization in the cell requires the infection of
every cell to provide enzymes for gene transcription.
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4.4.4.2.1 Transient transfection for protein detection in western blot analysis
Infection and transfection of the cells were performed as described above, but the cells were
infected with a moi of 10 p.f.u. The cells were scraped off in 0.5-1 ml medium, transferred into
a 1.5 ml Eppendorf tube  and spun down for 2 min at 8000xg in a benchtop centrifuge. The
pellet was resuspended in 300 ml 2x sample buffer for SDS-PAGE gel electrophoresis and
stored at –20°C.
4.4.4.2.2 Transient transfection for protein localization in electron microscopic studies
CEF cells grown in petri dishes (∆ 6 cm) to 80% confluency were infected with a m.o.i. of 10
p.f.u. in 2 ml MEM without supplements for 1.5 h.
2.5 mg DNA was diluted in 250 ml MEM and 8 ml Plus reagent, mixed and incubated for 15 min
at RT.
225 ml MEM and 12 ml LipofectAmin reagent were mixed, added to the pre-complexed DNA,
mixed again and incubated for another 15 min at RT.
The infection-medium was removed from the cells and the monolayers washed twice with
MEM. 2 ml MEM were introduced to the petri dish, the transfection mix (500 ml) was added,
mixed gently by shaking and incubated at 37°C and 5% CO2. After 3 h the transfection-
medium was replaced by MEM containing 5% FCS and 1% antibiotics/antimycotics. 40 hours
post transfection the cells were fixed for electron microscopy analysis (see 4.6.2)
4.5 Generation and characterization of recombinant MVA
High rates of recombination occur within poxvirus-infected cells. The vaccinia virus genome
recombines on average once in 1000 replication cycles. Recombination does not require late
gene products and can also occur between virus-derived genomic DNA and transfected
plasmid DNA. The transfected plasmids contain an insertion cassette of the gene of interest
under control of a vaccinia virus specific promotor and the vaccinia virus K1L gene as a
selection marker. This cassette is flanked upstream and downstream by sequences
homologous to sequences of the MVA genome. The homologous sequences are chosen in a
way to allow site directed recombination into regions where deletions had occurred naturally
in the MVA genome.
The K1L gene is expressed early in infection and is required for replication of vaccinia virus in
rabbit kidney cells (RK13). Viral genomes rapidly eliminate direct repeats with the formation of
intra- and intermolecular recombination products. The K1L gene is flanked by lacZ-repeats,
allowing its deletion by intramolecular recombination.
4.5.1 Generation of rMVA by homologous recombination
4.5.1.1 Growth selection of recombinant MVA on RK13 cell monolayers
Since MVA wt is unable to replicate efficiently in RK13 cells, this cell-line is used for growth-
selection of recombinant MVA. In contrast to the usually plaque formation as a result of virus
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infection, RK13 cells show a different phenotype when infected with MVA containing the K1L
gene. The infected cell and the neighboring cells lose their growth inhibition achieved by cell-
cell contact and move towards the infected cell in the center, building a three-dimensional
aggregate.
The virus suspension from the transfection (see 4.4.4.1) was freeze-thawed 3 times,
sonicated in iced water for 1 min using a cup sonicator (Sonoplus DH 200, Bandelin,
Germany), plated on confluent RK13 cells in 6 well plates in dilutions from 10-1 to 10-4, and
incubated at 37°C and 5% CO2 for 72 hours. Three days after infection aggregations (foci) of
RK13 cells infected with recombinant MVA were picked in a 20 ml volume by aspiration with
an air-displacement pipette (Gilson, Villiers-le-Bel, France) and transferred to microcentrifuge
tubes containing 500 ml medium, and processed by freeze-thawing and sonication for further
infections of RK13 cell monolayers. In this first round it was recommended to pick 10-20
different foci (viral clones). Not all foci contain recombinant viruses, also transient expression
of the K1L gene in remaining plasmids allows wt MVA to grow on RK13 cells. In the second
passage such viruses show a negative growth. Cloning of recombinant MVA by passaging on
RK13 cells was continued until PCR analysis of viral DNA extracted from RK13 cells
confirmed to absence of wild type sequence (see 4.5.3.2). Screening for synthesis of target
protein by immunostaining of fixed cell monolayers (see 4.5.4.2) or Western blot analysis of
cell lysates (see 4.5.4.1)  was carried out.
4.5.1.2 Deletion of the marker gene K1L
After elimination of parental MVA ten-fold serial dilutions of the recombinant viruses were
used for infection of semi-confluent BHK21 or CEF cells grown in 6-well tissue-culture plates.
BHK21 and CEF cells show a strong cytopathic effect resulting in the lysis of the infected
cells, finally leading to the typical plaque formation („holes“ in the cell monolayer). Those
plaques were picked as described above. Absence of selective pressure allows the
elimination of the K1L-gene by intramolecular recombination. Recombinant MVA were
passaged until PCR analysis confirmed the absence of the K1L gene. K1L-free recombinant
viruses should regain their growth deficiency on RK13, which was tested in parallel by
infecting RK13 cell monolayers.
Cloning of recombinant MVA can also be carried out in 96-well plates. Wells containing one
single CPE were harvested in total, followed by the procedure described above. In view of the
fact that MVA produces a lot of extracellular enveloped viruses (EEV), which might
contaminate the selected clones, this method is advantageous for generating recombinants
and deleting the K1L-gene by avoiding EEV-spread using physical barriers.
Alternatively EEV-spread can be blocked by an agarose overlay. 2 h.p.i. the inoculum was
removed and cultures supplemented with a 1:1 mixture of 2x medium (MEM, 2% FCS) and
2% Low-Melting-Point Agarose (Gibco-BRL). In this case, the CPEs were picked by aspiration
using an inserted tip of a sterile cotton-plugged Pasteur pipette. Cells were scraped and
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aspirated together with an agarose plug by squeezing a rubber bulb on the Pasteur pipette
and the material was transferred to a tube containing 0.5 ml medium.
Recombinant viruses were amplified upon infection of BHK21/CEF cell monolayers (see
4.4.2.1).
4.5.2 Analysis of recombinant MVA-DNA
Recombinant MVA has to meet the demands of insertion of the foreign gene into the virus
genome, expression of the foreign protein and elimination of parental wt MVA and the host
range gene K1L.
In this work PCR analysis was used to check the elimination of wt MVA and K1L and the
insertion of the foreign gene.
4.5.2.1 Isolation of MVA-DNA
Recombinant viruses were grown at a high m.o.i. in 6-well tissue culture plates until strong
cytopathic effects of the cell monolayer were visible (usually the 10-1 dilution of a passage
was sufficient). The cells were scraped off in 0.5-1 ml medium, transferred into a
microcentrifuge tube and freeze-thawed three times to release the virions from the infected
cells. Cellular debris were removed by centrifugation for 5 min at 320xg in a benchtop
centrifuge. 350 ml supernatant containing the virus was introduced to a new Eppendorf tube,
mixed with 50 ml 10x TEN buffer, 5 ml proteinase K (10 mg/ml in 1mM CaCl2), and 50 ml 10%
SDS and incubated for 2-3 hours at 56°C.
The DNA was purified by phenol/chlorophorm extraction (see 4.2.2.1), precipitated with
ethanol (see 4.2.2.2) and eluted in 50 ml water or 1xTE buffer.
4.5.2.2 PCR analysis of recombinant MVA-DNA
MVA wt and recombinant DNA differ in size at the insertion-site of the foreign gene. Primers
NIHGS83 and IIIfl1B are chosen complementary to the flanking sequences. Three PCR
products can be distinguished (a schematic overview is depicted in Fig. 22C):
- wt DNA, amplification of the naturally deletion site:  ª 600 bp for deletion III
-  recombinant MVA including the K1L gene: ª 600 bp wt DNA + 1100 bp K1L gene +
foreign gene
- recombinant MVA: ª 600 bp wt DNA + foreign gene
MVA wt DNA and the transfected plasmids were used as controls. The reaction was carried
out in 0.2 ml PCR tubes in a total volume of 100 ml, using PCR Master (Roche)
MVA-DNA 10 ml (out of 50 ml ª 200-500 ng)
PCR Mastermix 50 ml (1x PCR buffer, 2.5 U Taq polymerase in Brij 35, 0.005% (v/v),
dNTP each 0.2mM, 10mM Tris-HCl, 50mM KCl, 1.5mM MgCl2)
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primers 5 ml each (10 pmol/ml)
H2O 30 ml
DNA was denatured at 94°C for 2 min and went through 30 cycles of:
DNA-denaturation 94°C, 1 min
primer-annealing 55°C, 1 min
elongation 72°C, 4 min
The reaction was stopped by an incubation of 7 min at 72°C, and cooled down to 4°C. 10-20
ml of the reaction sample were analyzed by gel electrophoresis (see 4.2.3.2). Since the PCR-
fragment for recombinant MVA still including the K1L gene might be quite big and therefore
difficult to amplify, the absence of the K1L gene was confirmed by testing the growth ability on
RK13 cells.
4.5.3 Detection of recombinant protein in MVA infected cells
4.5.3.1 Protein detection by Western blot analysis
Immunoblotting was performed as described (see 4.3.2). Polyclonal rabbit serum anti-CDV.H
was used at a dilution of 1:5000, anti-rabbit peroxidase in a dilution of 1:10000.
4.5.3.2 Protein detection by immunostaining
Proteins can also be detected in fixed and permeabilized monolayers of virus infected cells
using antibodies and horseradish peroxidase conjugates. The visualization occurs by adding
o-dianisidine the substrate for horseradish peroxidase. The procedure is shown for cells
grown in 6-well plates.
Medium was removed and the cell monolayers fixed and permeabelized with a 1:1 mixture of
acetone:methanol (1 ml per well) for 2-10 min at RT. The fix was removed and the
monolayers dried for some minutes. 2 ml PBS-2% FCS were added for blocking (1 h at RT or
O/N at 4°C) to minimize unspecific binding of the antibodies. The first antibody was diluted in
blocking buffer and incubated on the cells (2 ml/well) for 1-3 h at RT, by gentle rocking. 1st
antibody was removed and the cells washed three times with PBS to remove unbound
antibodies. 2nd antibody (horseradish peroxidase-conjugated, raised against the Fc-part of the
1st antibody) was diluted in blocking buffer, introduced to the cells (2ml/well) and incubated for
1-2 h at RT, rocking gently. Meanwhile a saturated solution of dianisidine (Sigma No. 09143)
in 500 ml absolute ethanol was prepared, vortexed thoroughly and stored in the dark for at
least 30 min. Undissolved dianisidine was pelleted briefly, 200 m l saturated dianisidine
solution was mixed with 9.8 ml PBS and filtrated (0.2 mm). 20 ml H2O2 (>30%) were added and
the substrate introduced to the cells (0.5-1 ml per well) after washing them 3 x with PBS.
Stained foci are visible within 5-20 min. The staining reaction was stopped by washing with
water or PBS.
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4.5.4 Multiple step growth curve
To investigate the ability of virus to productively grow in target cell monolayers this highly
sensitive method was established.
The number of target cells grown in one well of a 6-well plate was determined and virus
material homogenized by sonication was diluted in suitable medium to allow infection of target
cells at a m.o.i. of 0.05 infectious units (IU)/cell using a 1 ml volume per well. Growth medium
was removed, 1 ml virus suspension per well was added and adsorbed for 1 h at 37°C. The
inoculum was removed and the cell monolayers washed carefully three times with medium (2
ml/well) to remove free virus. 1.5 ml growth medium including 2% FCS and 1% AB/AM were
added per well and incubated at 37°C and 5% CO2.
At 0, 12, 24, 48, 72 hours after infection supernatant and cell lysate of the infected cultures
were harvested separately. The supernatant (containing EEV) was transfered to an
Eppendorf tube, 1.5 ml growth medium was added to the cell monolayer, cells (containing all
cell associated viruses) were scraped off and transfered with the medium into a new
Eppendorf tube. Aliquots were frozen and stored at –80°C.
To determine the amount of infectious virus present at the various times after infection, the
cell lysates were freeze-thawed (3x) and sonicated, the supernatant was used fresh directly
after harvesting and titrated as described (see 4.4.3).
Alternatively, this method can be carried out in 12-well plates, using 0.5 ml inoculum and 1 ml
growth medium.
4.5.5 Virus purification on CsCl gradients
This procedure allows to separate different enveloped virus particles according to their
density. Enveloped viruses such as EEV and CEV sediment at a buoyant density of about
1.24 g/ml, whereas a density of 1.27 to 1.28 g/ml is characteristic for IMV.
4.5.5.1 Separation and concentration of virus fractions
Confluent CEFs grown in 7 cell culture flasks T225 were infected at an m.o.i. of  0.1 or 10
p.f.u. in 35 ml medium/flask and harvested at 50 h.p.i. or 40 h.p.i. respectively.
Extracellular fraction:
Medium was harvested, the cell monolayers washed with 10 ml PBS/flask, and the PBS
pooled with the medium in a 50 ml Falcon tube. The supernatant was clarified by
centrifugation at 1000xg and 4°C for 30 min. The clarification was repeated until the
suspension was very clear. The supernatant was introduced in Beckmann ultraclear
centrifuge tubes and pelleted for 1 h at 40000xg and 4°C in a Beckman Optima LE-80K
Ultracentrifuge using a SW 28 rotor. Pellets were pooled and resuspended in 7 ml TMN buffer
(see 3.2).
Cell associated fraction:
5 ml Trypsin/EDTA were introduced into each flask and incubated on the monolayers until cell
detachment. During this procedure CEVs detach from the cells. Cells and trypsin were pooled
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and introduced into a 50 ml Falcon tube containing 10 ml FCS to stop the trypsin reaction.
The sample was clarified twice at 1000xg for 30 min. The supernatant (CEV fraction) was
pelleted and resuspended in TMN as described above.
Intracellular fraction:
The remaining pellet after clarification of the cell associated fraction was resuspended in 45
ml PBS,  freeze-thawed and sonicated 3x to disrupt the cells and release the intracellular
viruses. Clarification and concentration was performed as described above.
For using these fractions directly in Western blot analysis 5 T225 flasks were infected, the
pellets were resuspended in 600 ml TMN buffer and stored at –80°C.
4.5.5.2 Sucrose cushion
4 ml of sterile 25% (w/w) sucrose in TMN buffer in a 12 ml ultraclear centrifuge tube
(Beckmann) were carefully overlaid with 7 ml virus suspension. The virus fractions were
centrifuged for 2 h at 160000xg and 4°C in a SW 41 rotor through the sucrose cushion. The
pellets were resuspended thoroughly  in 0.5 ml TMN buffer and sonicated briefly before being
layered over a preformed CsCl gradient.
4.5.5.3 Cesium chloride gradient (Payne and Norrby, 1976)
The gradients were prepared one day before the centrifugation. CsCl solutions in TMN of
different concentrations (r = 1.3, r  = 1.25, r = 1.2) were made, the concentration adjusted by
measuring the viscosity with a refractometer:
r = 10.2402 h - 12.6483
r = concentration
h = density
CsCl gradients were formed in 12 ml ultra clear centrifuge tubes (Beckmann) using 2.5 ml of
1.3 g/ml, 3.75 ml of 1.25 g/ml and 5 ml of 1.2 g/ml and equilibrated over night at 4°C.
Virus suspensions were loaded on the gradient and centrifuged for 1 h at 18°C and 180000xg
in a Beckmann Ultracentrifuge using a SW 41 rotor. Fractions (ª 0.5 ml) were collected from
the bottom of the tube. The absorbance at 280 nm and the density of each fraction were
measured. Fractions corresponding to viral peaks were used for further analysis.
4.6 Electron microscopic analysis
EM analysis allows a direct observation of infected cells or single virus particles. Studies were
carried out with a Philips 400T electron microscope, using magnifications of 8000 to 17000. In
this work two different methods were used.
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4.6.1 Immunolabeling and negative staining of viral particles
Purified virus particles obtained after CsCl density centrifugation are already characterized
due to their envelopment by the buoyant density of their sedimentation. The following
procedure allows to investigate the state of the particles and the associated proteins.
FormVar-coated copper grids (1% FormVar in chlorophorm) were carbonated and made
hydrophilic by submitting them to a glow discharge. Labeling was performed by floating the
grids on solutions placed as droplets onto Parafilm sheets (Griffiths et al., 1983). Grids (300
mesh) were incubated on 20 ml virus suspension from CsCl gradient fractions corresponding
to viral peaks (as measured by OD260) for 10 min, washed in PBS and blocked for 5 min in 20
ml PBG (see 3.3). Antibodies were diluted in PBG as recommended, and the grids were
incubated on top of a drop of antibody solution for 15-20 min. After washing 6 times in PBS
grids were incubated for 15 min with anti rabbit protein A gold (10 nm), diluted in PBG
according to the manufacturers instruction. Grids were washed 6 x in PBS and 6 x in dddH2O,
negative stained and protected against collapse during air drying in a 4:1 mixture of 2%
methyl- cellulose and 3% uranyl acetate for 10 min on ice. Excess fluid was removed from the
grids by touching them with a filter paper, and the specimen were air dried while held in wire
loops.
4.6.2 Electron microscopic analysis of infected cells
In this work EM analysis of infected cells was used to quantify the different forms of MVA
virions (IV, IMV, IEV, CEV and EEV) at various time points of infection, using different
multiplicities of infection.
4.6.2.1 Infection and drug treatment
CEFs grown in petri dishes (∆ 6 cm) were infected with MVA at an m.o.i. of 10 or 0.1 p.f.u. in
2 ml serum free MEM for 1 h. Monolayers were washed twice with MEM, then incubated with
5 ml MEM (5% FCS) at 37°C and 5% CO2 until fixation.
In the case of drug treatment 10 mg/ml IMCBH (provided by Aventis Pharma, Frankfurt, stock
solution: 10 mg/ml) was added to the growth medium immediately after the infection and 500
ng/ml Brefeldin A (SIGMA, stock solution: 5 mg/ml in 75% ethanol) 14 h.p.i. respectively. The
drugs remained in the medium until fixation. IMCBH specifically inhibits release of EEV by
blocking the formation of IEV (Payne and Kristenson, 1979). The target of IMCBH is a 37 kDa
EEV protein, the gene product of F13L. This protein is essential for EEV formation (Blasco
and Moss, 1991). Brefeldin A causes the ER to fuse with the Golgi complex. Consequently,
membrane traffic is blocked and newly synthesized proteins can not leave the fused
ER/Golgi. The drug has been shown to block EEV formation most likely because EEV
membrane proteins are unable to reach the TGN.
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4.6.2.2 Fixation
Cells were fixed at various time points after infection. To the medium an equal volume of
fixing solution 1 (see 3.2)(leading to a final concentration of 4% PFA and 0.1%
glutaraldehyde) was added, and cells were fixed for at least 2 h at RT. Most of the fixing
solution was removed, until about 1 ml was left. Cells were scraped from the dish in the fix,
transferred into a 1.5 ml Eppendorf tube and pelleted at top speed for 2-5 min in a benchtop
centrifuge. The fix was removed and replaced by 0.5 ml fixing solution 2 without disturbing the
pellet.
Those fixed samples were stored at 4°C.
4.6.2.3 Epon embedding
Epon embedding requires cells fixed in 1% glutaraldehyde, the cell pellets were therefore
fixed once more with 1% glutaraldehyde in 200mM HEPES buffer pH 7.4 for 1 h at RT. The fix
was removed and the pellets washed 3 x with HEPES buffer for 5-10 min each, then 3 x with
water since HEPES is disturbing the osmium. Contrast is achieved by incubating the cell
pellet with a mixture of 1% osmiumtetroxide (OsO4) and 1.5% potassium ferrocyanide
(K3Fe(CN)6, light sensitive) in H2O for 20 min at RT in the dark. The cells were washed 3 x
with water, followed by 3 x washes with HEPES. Cells were slowly dehydrated, beginning with
two incubations in 50% EtOH for 10-15 min each, followed by an incubation in a saturated
uranylacetate solution (> 5%) in 70% EtOH over night. The next day the cells were washed 3
x in 90% EtOH for 2 min, then 3 x in 100% dried EtOH for 10 min each. Slowly the ethanol
was replaced by Epon, starting with a 1:1 mixture of Epon:100% dried EtOH. After an
incubation period of 30 min this mixture was replaced by 75% Epon and 25% dried EtOH, and
incubated for 2 h. Finally the cell pellet was incubated in pure Epon over night. Fresh Epon
was poured into an embedding mould and a tiny piece of the pellet (max. 1 mm) was
introduced to the outer side. The sample was incubated for several hours and polymerized
over night in the oven at 60°C.
4.6.2.4 Sample preparation
Epon embedded samples were trimmed to the appropriate size and pyramidal shape. Fine
sections of a thickness of about 70 nm were obtained by hand-driven or automatic cutting with
a Reichert ultracut microtome (Leica) using a diamond knife (Drukker). The cut sections
floated on the surface of dddH2O at the back of the knife. Finally, they were transferred to
grids (hexagonal, 100 mesh, treated as described before) by dipping those into the water and
fishing out the floating sections carefully to avoid overlapping.
Contrast was achieved by incubating the grids in a closed glass petri dish for 25 sec in drops
of Reynold’s Lead Citrate in the presence of sodiumhydroxide pellets. Sodiumhydroxide binds
CO2 of the atmosphere, avoiding the precipitation of Pb. Grids were washed in dddH2O and
air dried.
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4.7 Immunofluorescence
CEF cells grown on 11 mm coverslips for 24 hours were infected at an moi of 5 of MVA. At 16
hours p.i. the cells were washed with PBS and fixed for 10 min at RT with 3% PFA in PHGM
buffer. The fix was washed away with PBS and the coverslip was incubated cell side down on
a drop of 30 ml rat anti-B5R in PBS supplemented with 5% FCS and 10mM Glycine for 20-30
min at RT. Surplus of the first antibody was removed by washing the coverslip 3-4 times over
10-15 min in PBS with 10mM Glycine. The infected cells were introduced to the second
antibody (anti-rat FITC) for 20-30 min in the dark. This first labeling was applied for staining
CEVs on the cell surface.
Subsequently, the cells were permeabilized with 0.1% Triton-X-100 in PBS for 10 min at RT.
After washing the cells 3-4 times as described above actin was stained with phalloidin-
rhodamine in PBS (5% FCS and 10mM Glycine) for 10-15 min. After a final washing step the
cells were embedded in 5 ml phenydiamine/moviol.
All records were done using the EMBL Advanced Light Microscopy facility. The resulting
digital images were edited using the Adobe 4.0 software package.
51
5. RESULTS
As outlined in the introduction, the clinical safety and immunological properties of
MVA makes this gene expression vector an important candidate for the generation of
recombinant live vaccines against different diseases. Improvement of the viral vector
can furthermore be achieved by the presentation of recombinant proteins on the
surface of the vaccinia virus particles. This would allow the induction of both humoral
and cellular immune response against the foreign antigen.
The extracellular enveloped form of vaccinia viruses was chosen as the particle of
integration, since these virions can easily be obtained from the supernatant of
infected cells without necessity of further purification. At the onset of this work little
was known about the production of EEV by this highly modified vaccinia virus strain.
Therefore, one focus of this work was to study the ability of MVA to produce the
enveloped infectious form of vaccinia viruses in more detail.
Different laboratories work with slightly different MVA strains. Throughout this study
MVA passage 582, clone F6, described and characterized by Mayr (Mayr, 1975) and
Meyer (Meyer et al., 1991), referred here as wtMVA or MVA, was used.
5.1 Production of enveloped virus by MVA
The amount of EEV produced varies significantly depending on the vaccinia virus
strain and cell line used (Payne, 1979; Payne, 1980). The Western Reserve (WR)
and International Health Department-J (IHD-J) strain of vaccinia virus are derivatives
of the New York City Board of Health strain, and produce similar amounts of CEV but
differ in the extent of EEV formation (Blasco and Moss, 1992). VV strains which
produce large amounts of EEV, such as IHD-J, produce comet-shaped plaques if
incubated under liquid overlay, instead of sharply defined round ones as described
for WR (Appleyard et al., 1971). This comet-shaped plaque phenotype represents
unidirectional spread of virus from the primary plaque (comet head) to give rise to
secondary infections (comet tail).
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While generating recombinant MVA (rMVA) this comet-shaped plaque phenotype
was detected occasionally (Fig. 3), suggesting that this highly modified VV strain
might produce significant amounts of EEV.
Figure 3: Comets of recombinant MVA on RK-13 cells. Cells were infected with a low MOI of
MVA containing the K1L gene. At day 4 post infection this light microscopy picture was taken.
Several independent approaches were used to quantify the absolute and relative
amounts of the different viral forms made in primary chicken embryo fibroblasts
(CEF).
5.1.1 Determination of infectivity in the supernatant of infected
cell monolayers
EEV is the infectious virus form that is released into the medium without necessity of
cellular lysis of the host cell. Back titration of the medium collected at different time
points after infection of subconfluent cell monolayers directly reflects therefore the
amount of infectious viral progeny in the EEV form.
5.1.1.1 MVA produces extracellular enveloped virus
CEF cells grown in 6-well plates were infected with MVA at a m.o.i. of 0.05. Infecting
cells with a low m.o.i. is a very sensitive method to determine the ability of the virus
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to productively spread in target cells. Virions can undergo several rounds of DNA
replication, assembly, and dissemination. The experiment was carried out in
triplicate. It was found that MVA indeed produced detectable amounts of EEV (Fig.
4). The amount of infectious virus detected in the supernatant showed a 4.5 log10
step increase over a 48 hours period. Thus at the end of the experiment more than
30.000 times more virus was present in the supernatant than at the beginning. When
comparing the infectivity detected in the cell lysate to the one in the supernatant, the
former fraction had 1.5 to 2 log10 step more infectivity, meaning that 30 to 100 times
more intracellular than extracellular virus is produced. This result suggests that
compared to WR, that has been shown to produce 40 to 300 times more intracellular
than extracellular virus progeny, depending on the cell lines tested, MVA in CEFs
may produce only slightly more EEVs. In contrast, IHD-J may produce 6 to 14 times
more intracellular than extracellular virus and may therefore be a much better EEV-
producer than both WR and MVA (Payne, 1980) see also below.
5.1.1.2 MVA produces the highest amount of EEV in CEF cells
Ever since the study by Payne (Payne, 1979) it is clear that the efficiency of EEV-
formation depends on the virus strain as well as the cell type used. By comparing for
instance IHD-J infection in HeLa to RK-13 cells, Payne concluded that whereas in the
former cells only 7%  of the total infectivity was EEV, in the latter it was 25 to 40%.
Since MVA is severely host range restricted and replicates only efficiently in CEF and
BHK-21 cells (Drexler et al., 1998), a recombinant MVA was used for comparative
studies. MVA-ssP-K1L-gfp has the VV host range gene K1L and the green
fluorescent protein (gfp) incorporated into its genome. This recombinant virus was
generated and described previously (Staib et al., 2000). The K1L gene product
enables the virus to grow permissively in RK-13 cells, which allows to include this cell
line for comparison of EEV production.
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Figure 4: Growth of MVA in CEF cells. Subconfluent monolayers of primary CEF grown in 6-
well plates were infected with 0.05 m.o.i. wtMVA. Supernatant and cell lysate were harvested
separately at 0, 4, 8, 12, 24, and 48 hours post infection and back titrated (see 4.14).
Figure 5: Growth of MVA-ssP-K1L-gfp in RK-13 (blue), CEF (red), and BHK-21 (yellow) cells.
Cells were infected with m.o.i. 0.05, cell lysate (A) and supernatant (B) were harvested at 0,
12, 24, 48, and 72 h.p.i., and back titrated separately.
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BHK-21, CEF, and RK-13 cells were infected with MVA-ssP-K1L-gfp at a low moi,
cell lysates and supernatants were back titrated separately, as described in the
previous experiment. This comparison revealed that MVA resulted in the highest
intracellular and extracellular titers in CEFs (Fig. 5). While there is no significant
difference in the ability of the virus to produce intracellular virus in the 3 cell lines
tested (Fig. 5A), there is a clear difference in the production of extracellular virus.
Surprisingly, MVA produces most EEV in CEF cells, being 10 times higher than the
production in RK-13 and BHK-21 cells (Fig. 5B). These results indicate that CEF cells
were most suitable for further studies of MVA envelopment. All further studies were
carried out with wtMVA.
5.1.2 Quantification of the different viral forms of MVA
However, these experiments do not allow discrimination between IMV, IEV, and CEV
that are all cell associated. Therefore, the different viral forms, both intracellular and
extracellular were separated by CsCl gradients (see 4.15).
5.1.2.1 Purified MVA virions show a high percentage of envelopment
To distinguish between the cell associated CEV and IEV one further step of
separation was included. After removal of the medium the cells were not simply
scraped off, but trypsinized after a brief wash with PBS. Trypsin treatment has been
shown to release CEV from the cell surface (Blasco and Moss, 1992). Using this
method it was possible to work with 3 different virus fractions: the extracellular
fraction (containing EEV that is by definition free in the medium), the cell associated
fraction (containing CEV removed by trypsinization), the intracellular fraction
(containing IMV and IEV). These 3 fractions were purified separately as described in
methods (see 4.15).
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Figure 6: Separation of different viral forms produced in MVA infected CEFs by CsCl-
gradients. Confluent monolayers of CEF cells grown in 7 225 cm2 flasks were infected with
m.o.i. 1 wtMVA. At 40 h.p.i. supernatant (containing EEV), cell-attached virions (CEV), and
cells (containing IEV and IMV) were harvested and purified as described in methods The
cellular fraction had to be divided to avoid overloading of the gradient (C and D). After
centrifugation the gradients were fractionated from the bottom to the top of the tube and the
presence of viral particles was determined by OD280 measurements (blue graph). The optical
density of each fraction was subsequently determined (red graph). Peaks are corresponding
to EEV (A), CEV (B) IMV (fraction 4 in C and D) and IEV (fractions 9 and 10 in C and D each).
1
1.05
1.1
1.15
1.2
1.25
1.3
1 3 5 7 9 11 13 15 17 19 21 23
fractions
d
en
si
ty
 (
g
/m
l)
0
1
2
3
4
5
6
7
A
1
1.05
1.1
1.15
1.2
1.25
1.3
1 3 5 7 9 11 13 15 17 19 21 23
fractions
0
1
2
3
4
5
6
7
ab
so
rp
ti
o
n
 a
t 
28
0 
n
m
B
1
1.05
1.1
1.15
1.2
1.25
1.3
1 3 5 7 9 11 13 15 17 19 21 23
fractions
d
en
si
ty
 (
g
/m
l)
0
1
2
3
4
5
6
7
C
1
1.05
1.1
1.15
1.2
1.25
1.3
1 3 5 7 9 11 13 15 17 19 21 23
fractions
0
1
2
3
4
5
6
7
ab
so
rp
ti
o
n
 a
t 
28
0 
n
m
D
57
Virus particles can be separated according to their buoyant density by sedimentation
in CsCl gradients (Payne and Norrby, 1976). IMV bands in the CsCl gradient at 1.26-
1.27mg/ml. Since EEV consists of an IMV with one additional membrane it is less
dense and bands at 1.23-1.24mg/ml. Measurement of the absorbance at 280 nm was
used to detect the virus peaks in the gradient fractions. The peaks detected at that
density in the extracellular and cell associated fraction correspond to EEV and CEV
respectively (Fig. 6A and B). Notably, the CEV peak was about 3 times higher than
the EEV peak, indicating that the majority of enveloped virus is not released in the
medium, but remains attached to the cell surface. The intracellular virus fraction was
so concentrated, that the sample had to be divided in two to avoid overloading the
gradient. In this intracellular fraction more than half of the virus progeny banded as
the enveloped form (Fig. 6C and D), whereas less than half of the intracellular virus
banded as IMV.
Virions contained in the peak fractions were subsequently analyzed by negative
staining EM to confirm the identity of the different viral forms (see 4.16.1). For this,
antibodies to B5R and A17L were used; the gene product of B5R, p42 is an EEV
specific protein that is absent from the IMV (Engelstad and Smith, 1993; Isaacs et al.,
1992). A17L is a major membrane protein of the IMV (Jensen et al., 1996). The A17L
protein p21 is therefore covered by additional membranes in EEV, CEV and IEV
particles, and is not accessible for antibody labeling.
Virions corresponding to the IMV fraction labeled heavily with anti-p21 (Fig. 7A),
whereas the EEV specific protein p42 was absent from these particles (Fig. 7B),
defining those clearly as IMV. The outer envelope of CEV, IEV and EEV appeared
partially destroyed, most likely due to the virus purification procedure (Smith and
Vanderplasschen, 1998). Consequently, IMV particles were visible underneath the
disrupted outer membrane, showing a positive labeling with anti-p21 (Fig. 7C, E, G).
Nevertheless, labeling with anti-p42 showed the existence of an additional EEV-
specific membrane, confirming that the particles are enveloped (Fig. 7D, F, H).
Figure 7: (next page) EM-analysis of negative stained virus particles. Viral particles out of the
peak fractions were labeled with antibodies against A17L (anti-p21) and B5R (anti p-42),
respectively. The presence of those proteins is shown by gold particles (10 nm). A: IMV
labeled with anti-p21, B: IMV labeled with anti-p42, C: EEV labeled with anti-p21, D: EEV
labeled with anti-p42, E: CEV labeled with anti-p21, F: CEV labeled with anti-p42, G: IEV
labeled with anti-p21, H: IEV labeled with anti-p42.
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5.1.2.2 Enveloped virus is the major viral form in MVA infected CEFs
The relative amounts of infectious virus progeny produced by MVA was determined
by titration of the purified virions. CsCl fractions corresponding to viral peaks were
pooled (Fig. 7: fractions 7-14 for EEV, 7-14 for CEV, 2-6 + 2-6 for IMV, and 7-15 + 7-
15 for IEV) and back titrated. The relative amounts of infectious vaccinia virus virions
is shown in Fig. 8. Whereas EEV represents only 4% of infectious progeny, 12%
consist of CEV and 46% of IEV. This implies, that at the MOI used and at this time
post-infection in CEFs infected with MVA, 62% of the infectivity is contained in the
enveloped viral forms with only 38% in the IMV.
Figure 8: Relative amounts of virus forms in MVA infected CEFs estimated by their infectivity.
The infectivity was determined by back titration of the peak fractions (fractions 7 to 14 (EEV)
in A, fractions 7 to 14 (CEV) in B, fractions 2 to 6 (IMV) in C and D, fractions 7 to 15 (IEV) in C
and D). The relative infectivity was calculated by dividing the infectivity measured in the peak
fractions by the total infectivity contained in all fractions.
5.1.3 Effects of inhibitors of TGN-wrapping
Wrapping of Vaccinia virus was reported to be inhibited by Brefeldin A (Ulaeto et al.,
1995) and IMCBH (Hiller et al., 1981; Kato et al., 1969; Payne and Kristenson, 1979).
The target of Brefeldin A is the GTPase ARF-1; treatment of cells with this drug
causes the ER to fuse with the Golgi complex and consequently membrane traffic is
blocked. Because of this in VV infected cells EEV proteins fail to be targeted to the
TGN and wrapping is blocked. The target of IMCBH is the EEV protein F13L. Since
this protein is essential for TGN-wrapping, the drug inhibits the latter process.  The
aim of the following experiments was to see whether MVA envelopment was also
affected by these drugs and if this treatment would facilitate the isolation of pure IMV
(not contaminated by the IEV peak) needed for further experiments.
IMV
38%
IEV
46%
EEV
4%
CEV
12%
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5.1.3.1 Inhibition of envelopment by Brefeldin A
Cells were infected with a m.o.i. of 0.1, harvested 50 h.p.i. and purified by CsCl
gradient centrifugation as described above (see 4.5.6). In the case of Brefeldin A
treatment the drug was added at 500 ng/ml at 14 h.p.i.. Concentrations of Brefeldin A
higher than 0.1 mg/ml are toxic for CEFs when applied for more than 24 h (Boulanger
et al., 2000). Therefore, the drug could not be given to the medium immediately after
infection, but was added at 14 h.p.i. instead.
After Brefeldin A treatment (Fig. 9) three striking effects were visible. (1) The
absorbance peaks at 280 nm for EEV and CEV decrease from 1.2 in untreated cells
to 0.2 in treated cells and from 0.4 to 0.1 respectively. The latter values are very
close to zero, indicating that virus release from the cell as EEV or CEV is inhibited in
the presence of Brefeldin A. (2) The amount of IMV measured at 280 nm increases
dramatically from 0.4 and 0.5 in untreated to 2.9 and 4.3 in treated cells. This
indicates that in Brefeldin A treated cells viral particles accumulate inside the cell in
the IMV form (3). The absorbance peak of the intracellular fraction of untreated cells
that corresponds to the enveloped form of the virus, indicated by the buoyant density
of its sedimentation of 1.23-1.24 mg/ml, shifts in the presence of Brefeldin A to a
density of 1.24-1.25 mg/ml. This density is not characteristic for a specific viral form,
but may indicate an incomplete wrapping of IMVs.
This suggestion was supported by negative staining Electron microscopy of particles
from the shifted peak (Fig. 10). IMVs with which large membrane sheets were
associated that labeled with anti-p42 were observed. This suggested that the IMVs
associated with membranes containing EEV proteins, but failed to wrap themselves.
This association of IMVs with membranes apparently resulted in a sedimentation in
the gradients in peaks lighter than IMV but slightly heavier than IEVs. In contrast,
completely wrapped enveloped particles showed a disrupted but always compact
pattern when stained with anti-p42 (see Fig. 7H for comparison).
Figure 9: (next page) Comparison of CsCl gradient purified virions grown in presence (B, D,
G, H) or absence (A, C, E, G) of 500 ng/ml Brefeldin A. CEFs were infected with a m.o.i. of
0.1 and EEVs (A and B), CEVs (C and D) and intracellular virus (E to F) harvested at 50
hours post infection. Density and absorption at OD280 were measured as in fig. 6.
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Figure 10: Incompletely wrapped IMV particle. Treatment with Brefeldin A caused an
absorbance peak at a density of 1.24-1.25 mg/ml representing a density between the IMV and
enveloped form. Virus particles out of this fraction were negative stained and labeled with an
antibody against the EEV protein B5R. Membranes in close proximity to the IMV particle
labeled heavily with anti-p42, indicating that IMV particles associated with membranes
enriched in EEV proteins but did not wrap themselves completely.
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The inhibition of wrapping by Brefeldin A was confirmed by EM studies of Epon
embedded CEF cells infected with 0.1 m.o.i. of MVA in the presence and absence of
the drug, and fixed 50 h.p.i. (see 4.6.2). An overview of characteristic cell profiles
show the presence of viruses in all stages of maturation in untreated cells, although
CEVs appeared to predominate (Fig. 11A and C).  In Brefeldin A treated cells,
however, IMVs accumulate and no obvious TGN-wrapping nor CEVs could be
detected (Fig. 11B).
Figure 11: Inhibition of TGN wrapping by treatment with Brefeldin A. CEF cells were infected
with moi 0.1 in presence (B) and absence (A and C) of Brefeldin A, and fixed 50 hours post
infection. Without drug treatment the entire cells are covered with CEVs (C), in a higher
magnification the outer envelope of these particles is visible (arrow), (✻) indicates an IEV (A).
In drug treated cells IMVs accumulate (B).
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5.1.3.2 Inhibition of envelopment by IMCBH
CEF cells were infected with a m.o.i. of 10 with wtMVA, in presence and absence of
10mg/ml IMCBH, fixed 24 h.p.i. and prepared for EM analysis as described in
methods (see 4.6.2). The different viral forms were counted in 15 profiles of infected
cells and expressed as percentage of the total viral forms detected (Fig. 12).
It has to be mentioned, that EEVs can not be quantified by this method, since only
cell associated virions are detectable.
Figure 12: Inhibition of TGN wrapping of MVA in CEFs by IMCBH. CEF cells infected with
MVA in presence (yellow) and absence (blue) of IMCBH. Treatment with IMCBH shows
almost complete inhibition of envelopment.
Clearly, these results show that IMCBH inhibits MVA TGN- wrapping. CEV represent
36% of infectious viral progeny in the untreated control cells, whereas no CEV was
detected in IMCBH treated cells. Also, the amount of IEV decreases from 19% to 2%,
whereas the amount of IMV increases dramatically from 33% in untreated cells to
92% in drug treated cells.
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5.1.4 Influence of m.o.i. and time on the formation of
enveloped virus
For detection of EEV and measurement of the efficiency of MVA to spread
productively in target cell monolayers, the highly sensitive method of a multiple step
growth curve was used, which means infection of the cells with a low m.o.i. and
monitoring of the virus progeny 50 hours post infection. For EM analysis the cells
were infected with a m.o.i. of 10 to make sure, that all cells are infected. Furthermore,
the cells were fixed 24 h.p.i. since the cells are then still in a healthy state, and the
different viral forms are well distinguishable from each other. Another classical time
point for EM analysis of vaccinia virus infected cells is 16 h.p.i., since then all viral
forms are present in the cell. By analyzing these data it could be shown that relative
distribution of the different viral forms of vaccinia virus is time- (Fig. 13A) and  moi
dependent (Fig. 13B).
Figure 13: The different types of virus forms observed depend on time post infection and on
input infectivity. CEF cells were infected with 10 MOI and fixed at 16 (blue) and 24 (yellow)
h.p.i., respectively (A). CEF cells infected with 10 (blue) and 0.1 (yellow) IU/cell were fixed at
24 h.p.i. (B). Virus forms in 50 randomly chosen cell profiles each were counted.
At 16 hpi many immature virions or crescents were still detectable, whereas more of
the infectious viral forms were detectable at 24 h.p.i. In particular the amount of CEV
increases, reflecting that over time these virions accumulate on the surface of the
infected cell. The multiplicity of infection seems to influence the efficiency of
wrapping. The relative amounts of IEV and CEV are higher in cells infected with a
low m.o.i. compared to higher m.o.i. at 16 h. post infection.
These results show that the wrapping events in MVA are not only cell type
dependent, but are also dependent on the multiplicity of infection and on the time
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post-infection. It could be shown that TGN-wrapping occurs in MVA and that, under
the conditions tested, enveloped forms dominate over IMV. However, to be able to
assess how efficient the wrapping in MVA infected CEFs really is, a comparison with
well characterized and widely used vaccinia virus strains seemed necessary.
5.2. Efficiency of envelopment in MVA compared to
the well characterized vaccinia virus strains WR and
IHD-J
The most commonly used VV laboratory strains are IHD-J and WR. The two virus
strains are closely related to each other and differ in their ability to produce and/or
release extracellular enveloped viruses. Almost all studies concerning EEV
production have been carried out with these two VV strains. IHD-J produces high
yields of EEV, whereas WR releases little of this viral form. The above experiments
suggested that MVA in CEFs produced high amounts of the TGN-wrapped forms,
including CEVs. The next step was to compare EEV/CEV/IEV production by MVA in
CEFs, to the well established strains WR and IHD-J.
5.2.1 Quantification of the viral forms made by MVA, WR, and
IHD-J
All studies were carried out in CEF cells. The same growth curves as described
above were used including trypsinization of the cell monolayer to release CEVs from
the plasma membrane. This allowed assessment of the infectivity associated with
EEV, CEV and the intracellular virions. To distinguish between IMVs and IEVs that
are both intracellular, quantitative EM was used.
5.2.1.1 IHD-J produces most EEV
Subconfluent monolayers of CEF cells were infected with WR, MVA, and IHD-J at a
m.o.i. of 10. At 6 different times post-infection EEV was collected from the medium,
CEV was released from the cell surface by trypsinization, and IMV and IEV were set
free from the cells by freeze/thawing and sonication. The experiment was carried out
in triplicate and all samples were back titrated in duplicate. WR and IHD-J were
titrated on BSC-40 cells by cristal violet staining (see 4.4.3.3), MVA was titrated on
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CEF cells by immunostaining (see 4.4.3.2). It is shown in figure 14 at point 0 post
infection that the input virus used for infection with MVA was higher than for WR and
IHD-J. Nevertheless the results of this experiment show a clear tendency.
Figure 14: Time course of the production of infectious particles in CEFs infected with MVA,
WR, And IHD-J. Monolayers of CEFs were infected for one hour with MVA (blue), WR (red),
and IHD-J (yellow) at a moi of 10. Cells were washed and intracellular virus (A), CEVs (B),
and EEVs (C) harvested at the indicated times post infection. The average infectivity
contained in each sample is expressed as plaque forming unit (pfu) per ml. The standard
deviation is shown as error bars. During the course of this experiment it appeared that the
amount of infectivity measured at 0 h.p.i., which measures the virus that remains attached to
the plasma membrane after absorption, was slightly higher (about 0.5 log) upon MVA
infection. This is due to the fact that the MVA stock used throughout these experiments was
titrated in a different way (by immunostaining, rather than by crystal-violet staining) compared
to the two other viruses, making it difficult to directly compare the titers of the virus stocks. It
thus appeared that the MVA time course was done by infecting with a slightly higher MOI than
the two other viruses.
The results revealed a number of striking observations. First, IHD-J infection clearly
resulted in the highest titers of EEV in the extracellular medium (Fig. 14C).
Comparison of the intracellular titers revealed that MVA replicated with a faster
kinetic than the two other viruses (Fig. 14A). At 8 h.p.i., for instance, the infectivity
associated with lysates of MVA infected CEF was about 2 log10 higher than upon
infection with the two other virus strains. This faster growth kinetics apparently also
resulted in efficient CEV production (Fig. 14B) since at 8 and 12 h.p.i. MVA also
produced about 2 log10 higher yields of the latter virus form compared to WR and
IHD-J. At later time points this difference in CEV production was not so pronounced
anymore and at 48 h.p.i. almost equal amounts of infectious CEV were detected in all
three viruses.
When the production of CEV and EEV is compared per viral strain (Fig. 15), it is
obvious that in IHD-J EEV production exceeds CEV infectivity. WR and MVA,
however, produce more CEV than EEV. When the relative distribution of the
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infectivity contained in the different fractions at 24hrs post-infection was compared
(Fig. 16A) it was evident that IHD-J makes 13% EEV at that time of infection, while
MVA and WR make only 1-2 % of this viral form. IHD-J and WR have a similar
percentage (27% and 25% respectively) of the infectivity associated with CEVs, but
in apparent contrast with the above, the relative infectivity contained in the CEV
fraction is only 16% in MVA. Instead it appeared that the bulk of the infectivity of this
virus was associated with intracellular virus (containing IMV and IEV). In fact, the
relative infectivity for the different fractions correlated with the results obtained by
back titration of CsCl gradient purified virions (Fig. 8): 85 and 84% of the infectivity
was associated with intracellular virus, 15 and 12% associated with CEVs and 2 and
4% with EEVs in figure 16A and figure 8, respectively.
The combined results, however, show that EEV production by MVA is not particularly
high when compared to the classically used laboratory strains IHD-J and WR.
Figure 15: Comparison of EEV (blue) and CEV (red) production in CEF cells by WR (A), MVA
(B) and IHD-J (C). Data was obtained as described in fig. 14.
5.2.1.2 MVA produces most CEV
The infectivity time course experiment does not allow to discriminate between the
amounts of IMVs and IEVs made upon infection of CEF cells. Therefore, the extent of
envelopment of intracellular viruses was investigated by EM. For this CEF cells
grown in 6 mm petri dishes were infected with a m.o.i. of 10 with MVA, WR, and IHD-
J, respectively. Cells were fixed at 24 h.p.i. and embedded in Epon for EM analysis
(see 4.6.2). Obviously, this EM assay does not allow to quantify EEVs. Per VV strain
used, the three different viral forms (IMV/IEV/CEV) were counted in 50 randomly
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chosen profiles of infected cells and the absolute and relative amounts were
calculated.
Counts of the total amounts of the different viral forms produced at 24 h.p.i. revealed
that MVA infection resulted in the highest number of intracellular viruses. In 50 cell
profiles a total of 553 IMV and IEV were counted in MVA infected cells, but only 309
and 383 in IHD-J and WR infected cells, respectively (Tab. 3). The most striking
difference was observed in the amounts of CEV produced. MVA infection appeared
to result in about 3.5 fold more of these viruses at the plasma membrane compared
to IHD-J and WR, both of which produced similar amounts of CEV. Finally, upon IHD-
J infection 1.5 and 2 fold more IEV could be counted compared to MVA and WR
infections, respectively.
Table 3: Total amounts of IMV, IEV and CEV counted in 50 cell profiles at 24 hours post
infection in CEFs infected with WR, IHD-J and MVA.
VV strain IMV IEV CEV
WR 280 103 163
IHD-J 118 191 157
MVA 416 137 555
It was found that the relative amount of IMV is highest in WR (51%), intermediate in
MVA (38%) and lowest in IHD-J (25%). IEV, the precursor of CEV and EEV was with
41% very high in IHD-J, more than double of the percentages obtained in WR and
MVA infected CEFs, with 19% and 12% IEV, respectively. Most strikingly it was
found that for MVA 50% of the viral forms counted was CEV, considerably higher
than WR and IHD-J, that with percentages of 30% and 34% CEVs, respectively,
produced similar amounts of this viral form.
The EM analysis had shown that MVA produced the highest amounts of CEV
contradictory to the data obtained by measuring the relative amounts of infectivity,
where most of the infectivity appeared to be associated with intracellular (IMV and
IEV) virus upon MVA infection (Fig. 8 and Fig. 16A). These results could indicate that
perhaps CEVs produced by MVA were less infectious (CEV had a relatively low pfu
per particle ratio). Alternatively, the trypsin treatment was maybe less efficient in
removing CEVs from the plasma membrane of MVA infected cells compared to IHD-J
and WR infection. The latter possibility could be consistent with a number of
observations suggesting that the EEV envelope around the MVA particle is more
tightly attached to the underlying IMV and more resistant to rupture, compared to the
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two other viral strains (Sancho, 2002; Spehner et al., 2000). Since MVA infection
results in substantially more CEVs, failure to remove all of them from the cell surface
could result in higher titers of virus associated with the cell.
By comparing the EM data to the infectivities measured above, a general pattern
became discernable. IHD-J was the most efficient in the production of all of the TGN-
wrapped forms. This was not only shown by the fact that at 24 h.p.i. by EM 75% of
the virus was either IEV or CEV (with only 62% and 36% in MVA and WR,
respectively), but also that this virus resulted in the highest amounts of EEV
production as measured by plaque assay. Compared to WR MVA was also efficient
in TGN-wrapping, but off the released particles the bulk remained attached to the
plasma membrane. Finally, WR appeared to be least efficient in producing all of
TGN-wrapped forms.
Figure 16: Comparison of the relative amounts of the different viral forms detected by EM and
by titration, in CEFs infected with WR, IHD-J and MVA at a MOI of 10 and at 24 h.p.i. In panel
A the relative infectivities contained in intracellular virus (blue bars) , CEV ( yellow bars), and
EEVs (red bars) was calculated at 24 h.p.i. using the values obtained in figure 14. In panel B
CEFs were infected with WR, IHD-J and MVA and fixed at 24 h.p.i. Fixed cells were
embedded in Epon and the different viral forms, IMVs (blue bars), IEVs (green bars), and
CEVs (yellow bars) counted in 50 randomly chosen sections of infected cells. The values
represent the percentage of different viral forms relative to the total viruses counted.
5.2.2 MVA makes actin tails
The high amount of CEV detected by EM at the plasma membrane of MVA infected
CEF led to the question whether these viruses were able to induce actin tails as
shown extensively for WR and IHD-J.
7 3
8 3
6 0
2 5
1 6
2 7
2 1
1 3
0
1 0
2 0
3 0
4 0
5 0
6 0
7 0
8 0
9 0
100
WR (Titration) MVA (Titration) IHD-J (Titration)
Vaccinia virus strains
a
m
o
u
n
t 
o
f 
p
a
rt
ic
le
s
 (
%
) IMV/IEV
CEV
EEV
A
5 1
3 8
2 5
1 9
1 2
4 1
3 0
5 0
3 4
0
1 0
2 0
3 0
4 0
5 0
6 0
7 0
8 0
9 0
100
WR (EM) MVA (EM) IHD-J (EM)
Vaccinia virus strains
a
m
o
u
n
t 
o
f 
p
a
rt
ic
le
s
 (
%
) IMV
IEV
CEV
B
71
The A36R protein, which is characterized by its long cytoplasmic domain, is required
for actin-based motility and virus spreading. For intracellular transport and egress of
vaccinia virus a two-step model was proposed: IEVs are transported to the periphery
along microtubules, and actin tails form at the plasma membrane after IEV fusion
with the plasma membrane. Actin tail formation occurs from single viral particles,
which always remain at the tip of these structures. CEVs attached to the outside of
the cell continue to extend on those cellular projections, which can reach lengths of
over 20 mm.
Frischknecht et al. (Frischknecht et al., 1999b) have shown, that mutation of Tyr 112
and Tyr 132 in the A36R protein abrogates actin tail formation, and residues 71-100
(Rietdorf et al., 2001) are sufficient for IEVs to reach the cell periphery. In MVA all
those crucial amino acids and protein domains are unaltered, but the A36R gene
contains two in frame deletions (residues 139-147 and 216-219). Therefore, the
ability of MVA to induce actin tails was investigated.
CEF cells grown on cover slips and infected with MVA at m.o.i. 5 were fixed 16 hours
post infection. Before permeabilization, CEVs present on the cell surface were
labeled with an antibody to B5R, an EEV-specific membrane protein and a FITC-
conjugate. Afterwards, cells were permeabilized and intracellular actin stained with
phalloidin-rhodamine. In agreement with the EM observations, showing that some
cell profiles contained many CEVs at the plasma membrane, by immunofluorescence
the entire cell surface appeared covered with B5R positive CEVs (Fig. 17A).  Some
of theses viruses were clearly present on the tip of an actin tail (Fig. 17B). Attempts
to quantify by immunofluorescence how many of the CEV were attached to an actin
tail and to compare this number to WR infection were unsuccessful. It was found that
the MVA infection resulted in so many CEVs at the plasma membrane that the actin
tails were no longer visible and could not be counted accurately.
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Figure 17: Immunofluorescence microscopy of CEVs on actin tails in MVA infected chicken
embryo fibroblasts. Cells grown on cover slips infected and fixed as described above. CEVs
on the surface only were labeled with rat anti B5R and incubated with goat anti rat FITC
(shown as green dots in panel A). Cells were subsequently permeabilized with TX-100, and
actin was stained with phalloidin rhodamine (shown in red). Panel B shows a selected area of
panel A in a higher magnification. Arrow heads point to CEVs on tips of actin tails.
B
A
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5.3 Targeting a foreign protein to the outer envelope
of MVA extracellular enveloped virions
As outlined before EEV was chosen as a model of integration. The initial model
antigen consisted of the hemagglutinin of Canine Distemper Virus (CDV.H) of the
virulent A75/17 strain (Summers et al., 1984). CDV.H is an immunodominant antigen,
capable of eliciting fully protective antibody response against CDV (Pardo et al.,
1997; Welter et al., 1999).
Two different strategies were followed to target the recombinant protein to the
surface of extracellular enveloped virions:
Since it was shown, that non-VV proteins can be incorporated to some extent into the
EEV (Schmelz et al., 1994; Vanderplasschen et al., 1998b) native CDV.H (using the
full coding sequence of the hemagglutinin from the CDV strain A75/17) was inserted
into the MVA genome.
To increase the chance of incorporation of the CDV.H protein into the EEV, different
fusion-proteins were engineered, in which the transmembrane domain of CDV.H was
replaced by transmembrane anchors of known EEV membrane proteins (Roper et
al., 1998). Those proteins were expected to be targeted to the trans-Golgi network
(TGN), where the IMVs obtain their additional membranes to form the IEV and then
EEV.  This method was used successfully for targeting a chimeric human
immunodeficiency virus type 1 glycoprotein to the outer envelope of nascent vaccinia
virions, using the transmembrane and cytoplasmic domains of the vaccinia virus EEV
protein B5R (Katz et al., 1997). In this work the transmembrane domains of the EEV
specific genes A33R, A34R, and A36R were used.
5.3.1 Generation of recombinant MVA
During the attenuation process the MVA genome has suffered 6 major deletions.
Those naturally occurring sites of deletion have been used as insertion sites for
foreign genes. In this work the target genes were inserted into the deletion III site in
the MVA genome (Fig. 19).
Insertion plasmids flanked by sequences of MVA DNA allow precise insertion of
target genes into the selected site within the MVA genome by homologous
recombination (Fig. 19). Additionally, the plasmids contain the coding sequence of
the VV host range gene K1L under transcriptional control of its authentic promotor to
be integrated as a transient selectable marker to facilitate isolation of recombinant
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MVA (rMVA) by growth selection on RK-13 cells. Multiplication of MVA in rabbit
kidney-derived RK-13 cells, but not in other nonpermissive cells, can be restored by
insertion of the vaccinia virus K1L gene into the MVA genome. During nonproductive
infection of MVA in RK-13 cells, viral early mRNA is transcribed and persists for at
least several hours, but synthesis of virus-induced polypeptides occurs only during
the first hour and is followed by abrupt inhibition of all protein synthesis (Sutter et al.,
1994). Insertion of the K1L gene allows MVA infection to proceed to late stages of
viral protein synthesis in RK-13 cells leading to effective production of infectious
progeny (Sutter et al., 1994). Repetitive DNA sequences flanking the K1L gene were
designed to remove the marker gene from the viral genome by homologous
recombination under nonselective growth conditions in BHK-21 cells. The principle of
this procedure is depicted in fig. 19, and the procedure is described in detail in 4.5.
CDV.H is a type II membrane glycoprotein. Group II integral membrane proteins have
the N-terminal domain on the cytosolic side and expose the C-terminal domain on the
extracellular side. These proteins possess a signal sequence at or near the N-
terminus, which is combined with an anchor sequence for integration into the plasma
membrane. Plasmids containing genes for chimeric proteins were obtained form
Riccardo Witteck, Switzerland. The chimeric genes consisted of the extracellular
domain of CDV.H and the transmembrane domain of the EEV specific VV proteins
A33R, A34R and A36R, respectively (see Fig. 18), all of which were thought to be
group II transmembrane proteins too. The idea was that the signal sequence in the
transmembrane domain of the EEV specific proteins should target the extracellular
domain of CDV.H to the surface of EEV particles.
Figure 18: schematic presentation of chimeric proteins. TM = tansmembrane domain of VV
EEV proteins. A33R TM = AA1-AA60 of VV strain IHD-J, A34R TM = AA1-AA34 of VV strain
IHD-J, A36R TM = AA1-AA25 of VV strain WR. Extracellular domain of CDV.H = AA56-
AA608 of CDV.H strain A75/17. Constructed by Paul Howley, Institut de Biologie Animale,
Universite Lausanne, Switzerland.
TM Extracellular domain of CDV.H
N-term C-term
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Figure 19: Generation of recombinant MVA by homologous recombination. The vector
plasmids pIIIdHR are created to insert foreign proteins into the deletion III of the MVA genome
(schematic shown as a HindIII restriction map). Flank 1 and flank 2 refer to MVA-DNA
sequences upstream and downstream the deletion III allowing the insertion of the target
genes into the MVA genome by homologous recombination. Rec2 indicates the position of a
283-bp repetitive MVA-DNA fragment homologous to the right end of flank 1, which allows the
deletion of the K1L expression cassette in a second recombination event, resulting in a
recombinant MVA containing only the target gene.
5.3.1.1 Construction of insertion plasmids
A double set of plasmids was constructed, placing the recombinant genes under
transcriptional control of either the natural vaccinia virus specific early/late promotor
P7.5 or the strong synthetic promotor sP. The plasmids were obtained by opening
the MVA insertion vectors pIIIdHR-P7.5 and pIIIdHR-sP with PmeI in the multiple
cloning site (Staib et al., 2000). Blunt inserts A33R-CDV.H, A34R-CDV.H, and
CDV.H were cloned into the dephosphorylated vector DNA (see 4.2.1). The insertion
of the target genes into the expression vector and the correct orientation of the insert
were confirmed by restriction analysis. For each insertion plasmid two positive clones
were amplified.
HindIII map of the MVA
VV K1LFlank 1
rec rec
Target gene Flank 2VV/P
1.recombination
Deletion III
Flank 1
rec
Target gene Flank 2VV/P
2. recombination
76
Before generating the recombinant viruses the synthesis of the foreign proteins was
checked by transient expression experiments. Therefore, MVA infected BHK-21 cells
were transfected with equal amounts of the different insertion plasmids. Cell lysates
from these cells were assessed by western blot analysis using a rabbit serum against
CDV.H (Fig. 20). The specificity of the antibody was confirmed by transfection with
the empty plasmids and by a mock control.
Figure 20: Transient protein expression. BHK-21 cells grown in 6-well plates were infected
with m.o.i. 10 MVA and transfected with 15 mg plasmid DNA each: pIIIdHR-sP (lane 1),
pIIIdHR-sP-CDV.H (lane 2+3, pIIIdHR-sP-A36R-CDV.H (lane 4+5), pIIIdHR-sP-A34R-CDV.H
(lane 6+7), pIIIdHR-sP-A33R-CDV.H (lane 8+9), and mock (lane 10). Bands are detected with
an antibody against CDV.H.
Specific staining of a band of the predicted molecular weight of ca. 75 kDa was
detected for CDV.H wt (Fig. 20). The different fusion constructs generated different
results. Clearly the highest expression was achieved using the transmembrane
anchor of A33R. In contrast, either lesser amounts of recombinant protein (A34R-
CDV.H) or recombinant protein of a different molecular weight (A36R-CDV.H) were
obtained using the other VV EEV transmembrane anchors. Corresponding results
were achieved by immunostaining of RK-13 cell monolayers after infection with the
cell lysate of infected and transfected BHK-21 cells. The ratio of detectable
cytopathic effects (CPE) in total versus CDV.H-positive stained CPEs was best for
the A33R-CDV.H fusionprotein. Generally, the VV early/late promotor P7.5 provided
a higher transfection efficiency than the strong synthetic promotor sP. The A36R-
CDV.H construct was not used in the further experiments because of the expression
of a truncated protein. Some time later it was published that A36R is a type Ib
membrane protein, anchored with its N-terminus in the membrane but exposing the
1 92 3 4 5 6 7 8 10
CDV.H
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C-terminus into the cytosol (Rottger et al., 1999). Furthermore, A36R was shown to
be present only on the outer envelope of IEV particles but not on CEVs (van Eijl et
al., 2000), and was therefore not suitable for this project.
5.3.1.2 Plaque purification of recombinant MVA
BHK-21 cells were infected with a low m.o.i. of wtMVA and transfected with a surplus
of plasmid DNA. This combination allows the highest percentage of recombinant
MVA. The cell lysates of infected and transfected BHK-21 cells were diluted on RK-
13 cell monolayers to select for recombinant MVA. Wild type MVA is not able to grow
efficiently in RK-13 cells, only rMVA expressing the K1L gene product can replicate.
Cell aggregates, the typical cytopathic effect of MVA on RK-13 cells, were picked in
the highest dilution and distributed to a new round of plaque purification. During RK-
13 passages the expression of the proteins was routinely checked by
immunostaining (Fig. 21), and the absence of remaining wtMVA by PCR analysis
(Fig. 22).
Figure 21: Microscopy of fixed RK-13 cells infected with recombinant MVA expressing
CDV.H. Cell aggregates form on RK-13 cells upon infection with MVA expressing the K1L
gene. Cells were fixed on day 3 post infection and stained with anti-CDV.H (see 3.13.2).
Recombinant MVA was plaque purified by serial passages on RK-13 until elimination
of wtMVA. Wild type free recombinant MVA was plaque purified by passages on the
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MVA permissive cell line BHK-21 to delete the K1L gene in the absence of selection
pressure by an intramolecular recombination event (Fig. 19).
Recombinant MVA with the native CDV.H (MVA-P7.5-CDV.H) and the A33R-CDV.H
fusion protein (MVA-P7.5-A33R-CDV.H), both under transcriptional control of the
vaccinia virus early/late promotor P7.5, were successfully generated. The
construction of a recombinant virus containing the A34R-CDV.H fusion protein failed
as well as the construction of rMVAs with the target genes under the control of the
strong synthetic promotor sP, which was designed to overexpress the target proteins
to obtain a high abundance of foreign protein on the surface of EEV. During the
plaque purification all of them lost their ability to grow on RK-13 cells after a few
passages and/or did not express the foreign gene any more.
MVA-P7.5-A33R-CDV.H was obtained after 7 passages on RK-13 cells to eliminate
wtMVA and 6 passages on BHK-21 for deletion of the K1L gene. MVA-P7.5-CDV.H
was obtained after 3 passages on RK-13 and 4 passages on BHK-21, respectively.
5.3.1.3 Characterization of recombinant MVA
The obtained recombinants were characterized for genetic stability and clonal purity
by PCR analysis of the viral DNA using primers complementary to the flanking
regions of the insertion site (see 4.5.3). Hereby, the presence of a stably integrated
recombinant DNA was confirmed as well as the absence of any wildtype DNA and
the selective marker gene K1L (Fig. 22A). The original K1L gene of Vaccinia virus
Ankara was only partially deleted during the attenuation process that had lead to the
generation of MVA. Remains of the gene are still present at the deletion II site. In
some cases recombination events occur between the K1L sequence in the plasmid
DNA and the remaining K1L sequence in the MVA genome leading to a genomic
aberration. Therefore, the region of the deletion II site was tested for changes in size
by PCR analysis, using primers complementary to MVA sequences upstream and
downstream the deletion II (Fig. 22B).
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Figure 22: PCR analysis for insertion of the foreign protein into the deletion III of the MVA
genome and deletion of the marker gene K1L (A), and unaltered site of deletion II (B). A:
Amplification of the deletion III using the primers NIH-GS83 and IIIfl1b results in a PCR
product of approximately 600 bp for the wtMVA. (lane 1). Amplification of the complete
insertion cassette including the K1L and the target gene with the same primers results in a
PCR product of about 4000 bp (pIIIdHR-P7.5-A33R-CDV.H in lane 2, pIIIdHR-P7.5- CDV.H in
lane 3). Recombinant MVA with the inserted target gene and the deleted marker gene show a
band of about 2900 bp after amplification of the genomic deletion III (lane 4: MVA-P7.5-A33R-
CDV.H, lane 5: MVA-P7.5-CDV.H). A schematic overview is depicted in panel C. Arrows
indicate primers. B: Amplification of the deletion II using the primers II 0011b-5’ and II 0011b-
3’ shows no genomic aberration of MVA- P7.5-A33R-CDV.H (lane 4) and MVA-P7.5-CDV.H
(lane 5) compared to wtMVA (lane 3). Lane 2 contains the H2O control and lane 1 the 1kb
ladder.
The unaffected ability of the recombinant viruses to productively grow in permissive
cells in comparison to wtMVA was confirmed in a multiple step growth curve (Fig.
23). Of special interest was the unaltered production of enveloped virions present in
the supernatant of the infected cells.
DNA of the recombinant MVA was isolated and the inserted genes including the
promotor region were sequenced to confirm the absence of any mutation. The
expression of the recombinant proteins was again verified by western blot analysis. A
kinetic study was performed to obtain more detailed information of the protein
production (Fig. 24). Although the cells were infected with the same moi of rMVA, the
fusion protein was produced more efficiently than the native CDV.H. The same effect
was detected by comparative immunostaining of infected CEF monolayers (Fig. 25).
K1L Target gene
Target gene
Wt Virus
Plasmid
Recombinant Virus
C VV/P
Flank Flank
4000 bp
600 bp
2900 bp
A
500 bp
1000 bp
B
1 2 3 54 1 2 3 54
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Figure 23: Productive replication of rMVA shown in a multiple step growth curve. CEF cells
grown in 6-well plates were infected with wtMVA ( wt), MVA-P7.5-A33R-CDV.H (  33), and
MVA-P7.5-CDV.H ( H) at m.o.i. of 0.05. Supernatant (sup) and cell lysate (lys) were
harvested separately at 0, 4, 8, 12, 24, and 48 hours post infection.
Figure 24: Expression of recombinant proteins in a time course experiment. BHK-21 cells
grown in 6-well plates were infected with 10IU/cell of MVA-P7.5-A33R-CDV.H (A) and MVA-
P7.5-CDV.H (B) for 1 h. Cell lysates were harvested at 0, 6, 12, 24, 48, and 72 h.p.i. 1/15th of
the total volume was applied to each slot. All the samples were treated equally at any time of
the experiment. The proteins were detected in western blot analysis by a rabbit anti-CDV.H
serum.
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Figure 25: Immunostaining of fixed BHK-21 cells infected with MVA-P7.5-A33R-CDV.H (A) or
MVA-P7.5-CDV.H (B). The recombinant proteins were detected by a rabbit anti-CDV.H
serum.
The functional integrity of the early and late expression of the promotor was tested by
western blot analysis in a time course experiment, where AraC, an inhibitor of DNA
synthesis, was added to the infected cells. Since vaccinia virus late gene expression
is dependent on DNA synthesis, no late genes are made in the presence of AraC. In
Fig. 26 the amount of protein detected in presence or absence of AraC reflects the
expression of the proteins early and late or early only, convincing the functional
ability of the promotor.
Figure 26: Expression of recombinant proteins in presence (B, D) or absence (A, C) of AraC.
Cells were infected with MOI 10 MVA-P7.5-A33R-CDV.H (A, B) or MVA-P7.5-CDV.H (C, D)
and harvested as in the time course experiment described above. In the case of drug
treatment 40 µg/ml AraC were added directly after the infection.
A B
A B
C D
A33R-CDV.H
CDV.H
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This data shows that the recombinant proteins are expressed, the promotor is
functional in both early and late phase and the DNA sequence of the genes is
unmodified. But for unknown reasons the fusion protein is expressed to a higher
extend than native CDV.H.
5.3.2 Localization of the recombinant protein
5.3.2.1 Recombinant proteins are present in the supernatant of infected
cells
A first attempt to determine the localization of the proteins was made by testing the
supernatant of infected cell monolayers for the presence of the foreign protein in
westernblot analysis (Fig. 27). Presence of the foreign proteins in the supernatant
can be an indication for the incorporation in EEV particles, also present in the
supernatant. As a control a rabbit serum against B5R, the most abundant protein in
EEV, was used. The B5R protein has the size of 42 kDa and forms also dimers in the
envelope (Engelstad et al., 1992). High amounts of B5R were found in the
supernatant, confirming the presence of EEV particles. Taking the same samples
and using the antibody directed against CDV.H, specific bands for CDV.H could be
detected for both rMVA, but not for wtMVA. Although the same quantity of material
was used, the staining for the native CDV.H turned out to be stronger than for the
fusion protein, which was designed to increase the efficiency of integration. This
result can be due to the fact that not only EEV particles are present in the
supernatant, but also cellular debris.
Figure 27: Western blot analysis of supernatant of BHK-21 cells infected with wtMVA lane 1),
MVA-P7.5-A33R-CDV.H (lane 2), or MVA-P7.5-CDV.H (lane 3) using serum against B5R (A)
or CDV.H (B).
1 2 3
B5R
Dimer
1 2 3
CDV.H
A B
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5.3.2.2 Recombinant proteins are present on CsCl gradient purified
enveloped particles
Since the detection of the foreign proteins in the supernatant of infected cell
monolayers was just a hint for their presence also on EEV particles, virus particles
were purified by CsCl gradients (Fig. 28). To obtain as much EEV as possible, cells
were infected at a low MOI, and the material was harvested 50 h.p.i. In parallel, virus
was grown in presence of Brefeldin A as described in 5.1.3.1 (Fig. 29). In these
conditions, enough material of all viral forms for further analysis was obtained.
Particles out of the peak fractions were then used in western blot analysis (Fig. 30).
Like in the western blot analysis carried out before, wtMVA showed no labeling for
CDV.H in any of the analyzed fractions, confirming the specificity of the antibody.
Heavy labeling was found in the IEV fraction of both recombinants. The fusion protein
was detected in a single prominent band of about 75-80 kDa, native CDV.H on the
other hand was also detected in a form of lower molecular weight, probably a
degradation product. EEV particles of both recombinants also showed labeling with
anti CDV.H, to a lower extent as the IEV particles, but with the same expression
pattern. Notably, CEVs were almost not stained, only a very faint band of the
predicted molecular weight could be detected for the fusion protein. This was also
true for the IMV particles of MVA-P7.5-A33R-CDV.H. Morphologically, CEVs and
EEVs are identical particles but the trypsinization used to isolate the CEVs might
have had an influence on the integrity of the protein leading to a changed
accessibility of the antibody.
The localization of the proteins was then studied by negative staining EM of purified
particles (Fig. 31). This technique is highly sensitive and allows the detection of
single proteins on individual virus particles. The wt control confirmed the absence of
any background staining in the CEV and EEV fraction (Fig. 32). In the IMV and IEV
fraction a minor cross reaction was detectable.
Figure 28: (next page) CsCl gradients of recombinant MVA. CEF cells were infected at a MOI
of 0.05 with MVA-P7.5-A33R-CDV.H (A, C and E) and MVA-P7.5-CDV.H (B, D and F),
respectively. At 50 h.p.i. EEV (A and B), CEV (C and D), and intracellular virus (E and F) were
harvested as described in fig. 6.  Again the intracellular virus had to be divided and loaded on
two gradients each, but only one of those is shown for each recombinant.
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Figure 29: CsCl gradients of the intracellular fraction of MVA-P7.5-A33R-CDV.H (A and B)
and MVA-P7.5-CDV.H (C and D) after treatment with Brefeldin A.
Figure 30: Detection of the recombinant proteins in CsCl-gradient purified particles. Virus
particles out of the peak fractions of CsCl-gradients corresponding to IMVs, IEVs, CEVs and
EEVs were measured due to their protein content. 7mg protein was applied per slot. The
recombinant protein was detected by a rabbit serum anti CDV.H (1 = wtMVA, 2 = MVA-P7.5-
A33R-CDV.H, 3 = MVA-P7.5-CDV.H).
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Figure 31: Micrographs of CsCl gradient purified virus particles of rMVA labeled with anti
CDV.H. The recombinant protein on IMVs (A and B), IEVs, (C and D), CEVs (E and F) and
EEVs (G and H) of MVA-P7.5-A33R-CDV.H (A, C, E and G) and MVA-P7.5-CDV.H (B, D, F
and H) was detected by a rabbit serum against CDV.H and 10 nm protein A gold.
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Figure 32: wtMVA particles stained with anti CDV.H. Virus out of the peak fractions of CsCl
gradient purified viruses was negative stained and labeled with rabbit serum against CDV.H
and incubated with 10 nm protein A gold. 100 randomly chosen particles were counted for the
presence or absence of gold particles.
Figure 33: Virus particles of recombinant MVA labeled with anti CDV.H. 100 randomly chosen
particles each were counted for the presence or absence of labeling.
Over 80% of the CEV particles of both rMVAs showed positive staining with anti
CDV.H (Fig. 33). This result is contradictory to the data obtained by western blot
where no notable band could be detected in the CEV fraction of any of the two
recombinant MVAs. The main difference between A33R-CDV.H and CDV.H particles
is, that the fusion protein was also highly present in the IEV and EEV fraction,
whereas positive staining for CDV.H in those fractions was extremely low for the
native CDV.H protein, also contradictory to the data obtained by western blot
analysis. Fig. 34 shows a possible explanation. As outlined before only IMV and CEV
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particles can be purified in a very clean way. The IEV and EEV fractions contain
cellular debris. Cellular membranes and vesicles labeled heavily with anti CDV.H are
frequently seen in those fractions. For MVA-P7.5-A33R-CDV.H also IMV particles
showed a labeling with anti CDV.H. This data suggests that the prominent bands for
the recombinant proteins, that were detected by western blot analysis, did not reflect
the presence of that protein on those particles, but was mainly due to contamination
with cellular debris despite the purification.
Figure 34: Micrograph of an EEV particle of MVA-P7.5-CDV.H labeled with serum against
CDV.H and protein A gold. The EEV particle itself shows a poor labeling with CDV.H,
whereas vesicles on the right side of the picture label heavily.
Since the outer envelopes of the viral particles suffer during the purification process,
most of the particles have lost parts of their envelope or even lost it completely.
Therefore, the relative distribution of CDV.H versus B5R as a marker for CEVs and
EEVs was examined (Tab. 4). Furthermore, it was possible to distinguish between
presence and absence of labeling, and the state of the envelopes and abundance of
the proteins was also characterized by counting the gold particles on virus surfaces.
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If CDV.H proteins are present on the envelope of EEV, the distribution pattern of
CDV.H labeling should correspond to B5R labeling. This is not clearly the fact. The
fusion protein seems to be abundant in IMVs, CEVs, and EEVs to almost the same
extent. The native CDV.H in contrast is preferentially located on CEVs, particularly
with respect to the weak labeling of this fraction with anti B5R. On the other hand,
there is no explanation for the weak labeling of MVA-P7.5-CDV.H EEV particles with
anti CDV.H.
MVA-P7.5-A33R-CDV.H MVA-P7.5-CDV.H
anti B5R anti CDV.H anti B5R anti CDV.H
IMV 69 208 0 47
CEV 1371 345 269 307
EEV 935 229 269 40
Table 4: CsCl gradient purified viruses were negative stained and incubated with antibodies
directed against B5R and CDV.H, respectively, followed by an incubation with protein A gold.
Gold dots were counted on 50 randomly chosen particles per fraction of each virus.
5.3.2.3 In infected cells native CDV.H is localized predominantly in the
cytoplasm and the A33R-CDV.H fusion protein in the ER
The localization of the recombinant proteins in infected cells was determined by cryo
EM (Griffiths, 1993). These experiments were part of a collaboration between the
group “viral vectors” from Gerd Sutter, GSF, Munich and the “vaccinia virus” group
from Jacomine Krijnse Locker, Cell Biology programme, EMBL, Heidelberg, and were
carried out by M.C. Sancho.
BHK-21 cells were infected with recombinant and wtMVA for 16 h, fixed and
prepared for cryo EM (Griffiths, 1993). Ultra thin sections were labeled with the rabbit
serum against CDV.H and B5R, respectively, and incubated with protein A gold. Fig.
35A shows a CDV particle labeled with anti B5R. A comparable abundance of
recombinant protein on the surface of CEVs was not detected, but at least some CEV
particles were decorated with a few gold dots confirming the presence of
recombinant protein on these particles. Also in this experiment the native CDV.H
appeared to be incorporated to a higher extent than the fusion protein. However, the
vast majority of labeling was not found to be associated with enveloped viral
particles. A33R-CDV.H was located predominantly in the ER (Fig. 35B) and in the
plasma membrane. Native CDV.H, on the other hand, did not show any preferential
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location, but seemed to be spread over the cytoplasm and cellular membranes and
vesicles (Fig. 35C). Additionally, the labeling for native CDV.H was very weak.
Taken together these results show, that the foreign proteins are incorporated into the
viral envelope to some extent, but not as specifically and not as dense as it was
expected. The transmembrane domain of A33R did not greatly promote targeting of
the foreign protein to the outer envelope of EEVs. The strong labeling for anti CDV.H
obtained in western blot analysis seems to be in most part due to contamination with
cellular membranes.
Figure 35: Micrographs of cryo sections. (A) CEV particles of wtMVA labeled with anti B5R.
(B) Heavy labeling of the ER with anti CDV.H detecting the A33R-CDV.H fusion protein. (C)
Native CDV.H located with cellular membranes and in the cytoplasm.
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6. DISCUSSION
The aim of the current work was to test whether foreign proteins could be targeted to
the surface of extracellular enveloped virus upon MVA infection in CEFs. For this, it
was first tested whether CEFs infected with MVA produced significant amounts of
EEV. Subsequently it was tested whether two proteins expressed by MVA-
recombinants were incorporated into such EEVs and to what extent. Using a number
of independent approaches the current study shows that MVA infected CEFs results
in a moderate production of EEVs, but appears to make substantially more CEVs.
The results also show that the replication competent VV strain IHD-J is more efficient
in TGN-wrapping and in releasing EEVs in the extracellular medium than MVA, while
WR is less efficient. Finally, the data show that the two proteins tested, CDV.H and
A33R-CDV.H, were incorporated into the EEV in MVA infected CEFs, albeit with low
efficiency. This may be in part due to the fact that both proteins were not efficiently
targeted and/or retained in the TGN.
6.1 The production of the different viral particles made
by MVA in comparison to WR and IHD-J
The WR and IHD-J strains of VV have been extensively studied previously to
compare the amounts of infectious virus associated with infected cells to the
infectivity released into the extracellular medium. Payne (Payne, 1979) described for
the first time that the production of EEV is virus strain and cell type dependent:
whereas IHD-J infection in RK-13 cells resulted in the release of 25 to 40% of the
total infectivity into the extracellular medium, in the case of WR this percentage was
less than 1%. In HeLa cells, however, IHD-J released only 7% of the total infectious
virus into the medium. Payne also showed that the amount of infectious virus
associated with infected cells was similar in WR and IHD-J infected cells. Until now it
is unclear why HeLa cells produce less EEVs compared to RK-13 cells. Two possible
explanations come immediately to mind. First, TGN-wrapping may be much less
efficient in these cells. Alternatively, the cytoskeleton-dependent transport of IEVs
and/or subsequent fusion with the plasma membrane to release EEVs/CEVs  may be
inefficient compared to RK-13 cells. A thorough analysis comparing WR and IHD-J
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infection in HeLa and RK-13 cells as described in this study is required to
discriminate between these two possibilities.
In two subsequent studies Blasco et al. (Blasco et al., 1993) showed that the
difference in EEV release between the WR and IHD-J strains may be partly due to
the fact that upon WR infection EEVs are not being released but remained mostly
attached to the plasma membrane in the form of CEVs. The authors showed that
upon trypsin treatment of WR and IHD-J infected BSC-40 cells the amount of
infectious virus that could be released from the cell surface upon WR infection almost
equaled the amount of infectious virus released into the extracellular medium in IHD-
J infected cells. These data strongly suggested that WR and IHD-J underwent TGN-
wrapping to a similar extent but whereas IHD-J/EEV was then released from the cell,
the same viral form in WR infection remained bound to the cell surface. The authors
subsequently showed that whether EEV remains cell associated or is released into
the medium is determined by a single amino acid (residue 151) difference in the
EEV-specific A34R gene. If this amino acid was changed in the WR gene to the
corresponding residue of the IHD-J gene, WR infection now resulted in substantial
amounts of EEV in the extracellular medium (Blasco et al., 1993).
As mentioned above, in all of the studies in which WR and IHD-J were compared
only two fractions were analyzed; the total  virus associated with cells (including IMV,
IEV and CEV) and released virus (EEV) and no distinction was made between IMV,
IEV and CEV. The current study for the first time uses a number of independent
approaches to determine the amounts of all four different viral forms made and
compared these in three different virus strains. The only study comparing MVA to a
replication competent VV strain is from Spehner et al. (Spehner et al., 2000) who
used the Vaccinia Virus Copenhagen strain, which is less well characterized than
WR or IHD-J for the production of the different types of particles. The current results
therefore clearly extend previous data. They show that in CEFs the IHD-J strain is
best at producing all of the TGN wrapped forms and releases the highest amounts of
EEV. WR is least efficient in wrapping and  more viruses accumulated intracellularly
in the form of IMVs. Interestingly, MVA behaved intermediate between these two
virus strains. Importantly, the results also show for the first time that different virus
strains may also differ in their efficiency of TGN-wrapping. IHD-J was most efficient in
this process, MVA intermediate and WR was clearly less good. This study thus does
not confirm the data by Blasco et al. (Blasco et al., 1993) that showed that WR
produced significantly more CEV than IHD-J, as we detected similar amounts of
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these viruses in both viral strains. The current data should, however, be interpreted
with caution as the efficiency of these processes may be cell type dependent.
In the study by Payne (Payne, 1980) the production of EEV and the relation to in vivo
dessimination was compared in 13 different vv strains (see also below). Among those
were also WR and IHD-J which were characterized by a low and high release of
EEV, respectively. Unfortunately the Ankara strain, the origin of MVA, was not among
the viruses tested. The reason why MVA in CEFs behaved intermediate between WR
and IHD-J remains unclear. A possibility is that MVA initially had all the hallmarks of
WR infection with relatively little TGN-wrapping and EEV release. During the
repeated passaging of the virus it has adapted to undergo more efficient TGN-
wrapping resulting in the production of more IEV and CEV compared to WR. An
alternative, that appears less likely, is that Ankara behaved more closely to IHD-J but
that during its passaging on chicken embryo fibroblasts has become less efficient in
TGN wrapping and EEV release. Sequencing of the MVA genome [Antoine, 1998
#169] has shown that all of the known genes encoding VV envelope proteins are
intact, with exception of the A36R ORF, which has two small internal deletions. A
number of other genes encoding proteins of unknown function are deleted or altered
in MVA and any of these or combinations of mutations may be responsible for the
particular phenotype of MVA with respect to formation of enveloped particles.
The most striking observation made was that MVA resulted in a dramatic
accumulation of CEVs at the plasma membrane of infected CEFs. This was not only
shown by the infectivity time course, but also by EM in which in some cell profiles the
entire cell surface appeared to be covered with these viruses. As mentioned above,
whether extracellular virus is released as EEV or remains attached to the plasma
membrane as CEV is determined by a single amino acid (Lys-151ÆGlu) in the A34R
gene (Blasco et al., 1993). Comparison of the published A34R sequence of MVA to
WR and IHD-J revealed that this amino acid at position 151 is the same as in the WR
gene and differs from the IHD-J gene. These data confirm that MVA, having a A34R
gene similar to WR, makes substantially less EEV and consequently extracellular
virus accumulates as CEVs. As mentioned above, the accumulation of CEVs at the
plasma membrane of infected CEFs could be the consequence of a relatively
efficient TGN-wrapping (this study) and transport of IEVs, that subsequently
accumulate at the cell surface upon fusion because they cannot be efficiently
released from this cellular membrane. Whether microtubule mediated transport of
95
MVA/IEVs was more or less efficient compared to WR or IHD-J was not investigated
in this study. The current study does indicate that MVA is capable of making actin
tails. This is despite the fact that the A36R gene, the protein responsible for both
kinesin dependent movement and actin tail formation lacks 13 residues (amino acid
139-147 and 216-219) compared to the WR and IHD-J genes. It should be
mentioned, however, that the efficiency of tail formation was not investigated, nor
was it compared to the two other virus strains.
Our data differ from the data by Spehner et al. (Spehner et al., 2000). In that study it
was concluded that MVA produced significant amounts of all of the TGN-wrapped
forms (74%) in CEF cells while under the same infection conditions the Copenhagen
strain of VV produced only 22% of all of these forms. The latter results were obtained
by separating the different viral forms by cesium chloride gradients and peak
fractions were detected by following 3H thymidine labeled particles. The amounts of
the different viral forms made was thus calculated by measuring the amount of
radioactivity contained in the peak fractions.  In this study both infectivity as well as
thin section EM were used to determine the relative amounts of the viral forms made.
In this study MVA was compared to WR and IHD-J instead of the Copenhagen strain.
In the Spehner et al. study only one time post-infection was studied, while the current
data are based on detailed time course of infectivity contained in different viral forms.
Throughout our study a moi of 10 was used most commonly, while in the Spehner et
al. publication a moi of 0.1 was used. Data obtained in our study shows, that infection
with a low moi leads to a higher extend of TGN wrapping and results in more
enveloped virus progeny than infection with a high moi. The question is whether all of
these differences can account for the fundamentally different conclusions the current
and the Spehner et al. study arrives at. Copenhagen strain is not expected to behave
fundamentally different from WR and IHD-J. It is difficult to conceive how the different
detection methods used in the Spehner et al. study could influence the amount of
IEV/CEV and EEV produced in CEFs. The most likely explanation for the
discrepancy thus appears to be the use of only one moi and only one time post-
infection.
The combination of the moi and the time post-infection used in the Spehner et al.
study could have severely biased the amounts of TGN-wrapped forms produced by
the Copenhagen strain in CEFs. A prediction is that Copenhagen behaves similar to
either WR or IHD-J. Thus, in a proper time course experiment Copenhagen can be
expected to produce similar amounts of the TGN-wrapped forms compared to WR or
IHD-J.  Finally, a much less likely explanation is that the TGN-wrapped forms of
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IEVs, CEVs and EEVs made in MVA infected cells have a very low pfu per particle
ratio compared to IHD-J and WR. Assuming that this is indeed the case, this would
imply that the infectivity time course experiment severely underestimated the total
amount of particles made upon MVA infection, providing perhaps an explanation for
the discrepancy between our current and the Spehner et al. study. This possibility
seems unlikely since a study by Sancho et al. (Sancho, 2002) strongly suggested
that the pfu/particle ratios of purified WR and MVA is, in fact, very similar.
6.2 Is MVA infection a suitable system to target
foreign proteins to the surface of extracellular
particles?
While these data clearly showed that MVA in CEFs undergoes significant wrapping
and CEV formation, they also show that this infection condition results in the release
of only little EEV. The question therefore arises whether proteins targeted to the
surface of CEVs are capable of inducing a humoral immune response and whether
this putative response is just as efficient as when the same protein is exposed on
EEVs.
In the study by Payne (Payne, 1980) the 13 different virus strains tested were
classified into three groups. Group one viruses were characterized by a high EEV
release and a high virulence in vivo, the representative being the IHD-J strain. Group
two, comprising WR, released little EEV in vitro but was also highly virulent. Finally, a
third group released little EEV and showed pour virulence as well. At the time when
these data were published it remained unexplained how WR could be virulent while
producing little EEV. Payne implied that in WR infected cells the virus must have
evolved a way of spreading independently of EEV formation. It was subsequently
shown that WR infection resulted in substantial amounts of virus attached to the cell
surface as CEVs (Blasco and Moss, 1992) (Blasco et al., 1993). The combined data
suggest that CEVs may be as efficient as EEVs in cell-to-cell spread. Although this
point has not been tested directly, it can be envisioned that CEVs bound to the tip of
a long actin tail containing plasma membrane protrusion, reviewed in Moss and
Ward, (Moss and Ward, 2001) may be just as efficient in infecting neighboring cells
as EEVs  that are free to diffuse in the extracellular environment.
A study by Katz and Moss (Katz and Moss, 1997) suggests that this may indeed be
so and that proteins exposed on CEVs are equally immunogenic as when exposed
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on EEVs. In their study a chimeric protein containing the transmembrane and
cytoplasmic portion of the B5R gene fused to the HIV-env protein was cloned into
both IHD-J and WR. Recombinant viruses containing the wild-type HIV-env was used
as a control. It was shown before that only the chimeric protein was efficiently
incorporated into EEVs (Katz et al., 1997). It was subsequently tested whether these
viruses induced antibodies to HIV-env. Whereas the recombinant carrying the wt
HIV-env did not induce a humoral response, the WR and IHD-J recombinants
carrying the chimeric protein were equally efficient in doing so. The authors therefore
concluded that the induction of antibodies could be efficiently induced by exposure of
the antigen on either EEVs or CEVs (Katz and Moss, 1997). Taking all of these data
together and considering the fact that MVA results in the production of significant
amounts of CEVs, the conclusion must be that indeed MVA could be a good
candidate for targeting of foreign proteins to the surface of EEV/CEV. What should
be kept in mind, however, is that the assembly of MVA may be blocked in most
mammalian cells and therefore IEVs/CEVs in cell lines of interest may not be
produced. In this respect it is worth mentioning that preliminary results in the Krijnse
Locker laboratory indicated that  HeLa cells, the most commonly used cell line of
human origin, infected with MVA efficiently secrete immature viruses lacking MVA
genomes. These viruses are secreted by virtue of the fact that they undergo TGN-
wrapping and subsequent release in a way similar to EEV release. This observation
opens up a unique opportunity to target TGN-derived foreign proteins to the surface
of these non-infectious particles. It therefore also remains to be investigated in detail
at what stage MVA is blocked in cells that are the target of infection during
vaccination and whether those cells also secrete TGN-wrapped particles.
6.3 Targeting of CDV.H and A33R-CDV.H to the
surface of EEV particles
The rational of using the EEV specific membrane for targeting of foreign proteins
relies on a number of observations. First, EEV is the virus to be released into the
extracellular medium and thus can be expected to expose antigens to the immune
system. Second, in contrast to the IMV membranes that may exclude host proteins
(Sodeik et al., 1993), the EEV wrapping membrane may be less selective. This was
demonstrated by the fact that this membrane readily incorporated complement
control proteins (Vanderplasschen et al., 1998b) and that by EM non-EEV membrane
proteins that are retained in the TGN can be found in the viral wrapping membranes
(Schmelz et al., 1994). Efficient targeting to the EEV may, however, require specific
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targeting signals. In the above mentioned study by Katz et al. (Katz et al., 1997) , for
instance, it was shown that the HIV-env protein fused to the transmembrane domain
and cytoplasmic tail of B5R was incorporated significantly more efficiently into EEVs
than wild-type env. These data were subsequently confirmed by Mathew et al.,
(Mathew et al., 2001). In that study they used a virus in which the wild-type B5R gene
was deleted, which was shown before to result in a total block of EEV formation
(Engelstad and Smith, 1993). It was then tested which part of the B5R gene was
required to rescue EEV formation and it was found that these were the
transmembrane domain and cytoplasmic tail of the protein. They also showed, in
agreement with the data of Katz et al. (Katz et al., 1997) and Herrera et al. (Herrera
et al., 1998), that the entire luminal domain of the B5R gene could be replaced by the
corresponding luminal domain of the HA gene (A56R) attached to the
transmembrane region and cytoplasmic tail of B5R. Rescue experiments comparing
this chimeric protein to the full-length B5R gene showed that both proteins resulted in
similar amounts of EEV. It should be noted that already in 1998 Herrera et al.
(Herrera et al., 1998) had shown that the entire luminal domain of the B5R gene is
dispensable for EEV formation and that thus this region represents an ideal domain
to be swapped for foreign proteins (Herrera et al., 1998). The combined data thus
indicate that the B5R gene may be an ideal candidate for targeting of foreign proteins
to the surface of the EEV/CEV. Although less thoroughly investigated, one study
suggested that the transmembrane domain and cytoplasmic tail of the HA protein
(A56R) may also be a good candidate (Galmiche et al., 1997).
In the current study it was tested whether the transmembrane domains of the A33R,
A34R and A36R genes could also be used for targeting to the EEV. The data show
that the chimeric protein containing the membrane spanning domain of A36R
resulted in a product with a molecular weight expected of a clipped form of the fusion
protein. The reasons for this is unclear and was not further investigated. No
recombinant virus could be obained with the A34R chimera. Again the reason for this
is not clear at present; perhaps expression of the chimeric protein severely inhibited
IMV formation, or recombination repeatedly occurred at the wrong site of the genome
resulting in progeny that was no longer infectious. The chimeric A33R-CDV.H
resulted in a viable recombinant with a proper expression of the fusion protein that
was produced to high level and was stable. Unfortunately the data suggested that the
chimeric construct was not properly targeted to the TGN and instead was
predominantly retained in the ER. The most likely explanation for its failure to leave
the ER was that the protein was not properly folded resulting in its retention (see
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Doms et al., 1993 for a review). Consequently it was found that the wild-type CDV.H
protein incorporated more efficiently into EEVs then the chimeric construct.
The question that arises from these and other data is whether incorporation into the
IEV-wrapping membrane requires specific signals or whether any protein, that
transiently travels through the TGN, will incorporate into IEVs. The current data
suggested that a protein that is destined for transport to the plasma membrane can
be incorporated to some extent into EEV/CEV. Furthermore the study by
Vanderplasschen et al. (Vanderplasschen et al., 1998b) suggested that cellular
proteins that are not specifically retained in the TGN readily incorporate into EEVs as
well. Finally, EM data by Schmelz et al. (Schmelz et al., 1994) suggested that a TGN-
retained non-EEV membrane protein can be found in the wrapping membranes,
although it was not investigated if this protein was also present in the EEV.
A word of caution is required at this point. Most of the studies that tested whether
specific proteins are targeted to the EEV are based on western blots only. This
technique is prone to a number of problems. The least of those problems is that this
technique does not allow proper quantitation. A more serious problem deals with the
preparation of ‘pure’ EEV. It is clear that IMVs can be purified from infected cells to
about 95% purity (Jensen et al., 1996) and contain very little cellular contamination.
Consequently, by western blots the proteins of interest are never found in the IMV
preparation, used as a control in the experiments; a result that authors readily use as
a proof of specific incorporation into the EEV. It is not so clear, however, whether
EEVs can be obtained with the same purity as IMVs. At first glance it seems easy to
separate the extracellular particles from the rest of this same extracellular medium
that supposedly contains no other membrane-containing components. However,
upon negative staining EM, EEV preparations always contained substantial
contamination, some of which was heavily labeled with antibodies to EEV membrane
proteins. The origin of these EEV-positive membranes is not clear. However,
preliminary thin section EM observation suggest that VV infected cells may secrete
endosomal-like membranes in an exosome-like fashion, that contain EEV specific
proteins and that co-purify with EEVs (Sancho, Meiser and Krijnse Locker,
unpublished observations). Such contaminating membranes thus may severely bias
the extent of incorporation of non-EEV proteins as they may contain cellular proteins
unrelated to the EEV-wrapping process. Consequently, any study on the
incorporation of foreign proteins into the EEV should be accompanied by a thorough
EM negative staining inspection of EEV-preparations in which it should not only be
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tested whether the protein of interest is indeed exposed on the EEV, but also if and
how much contamination is present in the EEV preparation.
Another serious caveat of western blot analysis is its limitation in assessing how
efficient incorporation into the EEV really is. In fact negative staining EM, that is often
shown in parallel, does not help much. Such analyses often show a few gold
particles, frequently enhanced by using a so-called ‘bridging-antibody’ (this means
that the primary antibody was a mouse monoclonal, followed by rabbit anti-mouse
and protein-A gold). Such a labelling procedure often leads to binding of several
rabbit anti-mouse IgG to one IgG of the mouse monoclonal, leading to signal
enhancement; examples of this may be found in Katz et al. (Katz et al., 1997) and in
Vanderplasschen et al. (Vanderplasschen et al., 1998b), both groups used mouse
monoclonal antibodies, while the significance of attachment of these gold particles on
the surface of EEVs remains unclear. What is required is a thorough quantitation of
the amount of the protein of interest present in IMVs, IEVs, EEV and other
intracellular membranes. However, to perform such studies by western blotting is
very difficult because with the exception of the IMV, none of these particles, including
cellular membranes, can be purified without contaminating membranes. A possible
solution to this problem would be to conduct a thorough quantitative EM study. In
such a study a protein of interest is labeled with antibodies and the amount of
labeling is then quantified over all membranes of interest such as the ER, the TGN,
the wrapping membranes, the IEVs and CEVs. The comparative study will allow to
directly estimate the density of labeling over all of these different membranes and
eventually calculate the efficiency of incorporation into EEVs/CEVs by comparing the
density of labeling on these particles to the labeling in the TGN. Such a study could
be extended by assessing how well EEV membrane proteins are in fact incorporated
into the EEV.  Little is known about the efficiency of EEV-incorporation of EEV
membrane proteins themselves. If substantial differences are found when comparing
different EEV membrane proteins, such analyses could perhaps more directly predict
which EEV proteins would be more or less suitable for the generation of chimeric
proteins, carrying EEV specific targeting signals. Finally, each new chimeric protein
that is constructed could be conveniently, directly and rather quickly tested with
respect to its efficiency of incorporation into EEVs/CEVs using this method of
quantitative EM. Using MVA infection in either BHK or CEF in such analyses would
have the advantage that this virus results in a significant accumulation of CEVs at the
plasma membrane allowing one to conveniently quantify labeling over the TGN/IEVs
and CEVs in one section.
101
A start was made by quantifying by EM the labeling of the two different CDV.H
proteins and a number of observations were made that would not have been made
by any other technique. In particular it was found that the chimeric protein carrying
the A33R transmembrane domain was mostly retained in the ER and therefore failed
to be efficiently incorporated into the EEV. Other quantitative studies of this kind, in
which it will in particular be assessed if and how much of cellular proteins are
incorporated into IEVs and CEVs, are currently underway.
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